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Abstract 
Background 
 
There is no single test clinically available that is independently diagnostic for multiple sclerosis 
(MS). Currently MS is diagnosed using a combination of clinical evaluation and investigations 
including magnetic resonance imaging (MRI), interpreted in accordance with diagnostic criteria, to 
demonstrate the requisite dissemination of lesions in (anatomical) space and time.  
 
Lesions comprising inflammatory demyelination in the central nervous system are a core 
pathological feature of MS. Ultra-high field (e.g. 7 Tesla or 7T) T2*-weighted MRI can 
demonstrate in vivo a central vein in most of these lesions. This is a histopathologically specific 
feature which could be exploited to improve diagnostic workup in cases of suspected inflammatory 
demyelination. 
 
Central nervous system white matter not involved in demyelinating lesions is nevertheless affected 
in MS. The mechanisms inflicting injury to this normal appearing white matter (NAWM) and how 
they relate to focal lesions are unclear. Damage to NAWM seems important, because it correlates 
well with disability. Any association between cortical lesions, focal white matter lesions (WML) 
and diffuse damage to NAWM is difficult to investigate in vivo in MS, principally because MRI is 
relatively insensitive to cortical lesions. Investigation of such associations may also be confounded 
by the presence of small focal lesions within the “NAWM” that may remain undetected when using 
conventional MRI to define NAWM. Advantages inherent to ultra-high field MRI might help 
mitigate both of these problems. 
 
Objectives and methods 
 
2 
 
For any diagnostic test to be useful, it must be sensitive and specific at the onset of disease (not just 
adept at distinguishing long-established cases). We therefore prospectively investigated whether a 
single 7T T2*-weighted MRI brain scan could predict accurately (based on the presence of a central 
vein in brain lesions) an eventual diagnosis of MS in a group of patients referred to the Neurology 
clinic with diagnostic uncertainty. 
 
Even if a 7T MRI brain scan can be used to predict an eventual diagnosis of MS, 7T MRI scanners 
remain the preserve of research institutions, and are not used in routine clinical practice. In order to 
translate any benefit to clinical practice, such a technique must work using clinically available 
scanners. We therefore investigated whether a version of the protocol optimised for use with a 
standard clinical 3T MRI scanner could distinguish known cases of MS from brain lesions due to 
microangiopathic (i.e. small-vessel ischaemic) changes. 
 
One postulated explanation for some of the damage to NAWM in MS is that occult focal lesions do 
exist within the NAWM, which are beyond the resolution of conventional MRI scanners. We 
therefore compared lesion detection using 7T magnetisation prepared rapid acquisition gradient 
echo (MPRAGE) and 3T fluid attenuation inversion recovery (FLAIR) MRI brain scans in known 
cases of MS. 
 
To investigate potential associations between cortical lesions, WML and diffuse damage to NAWM 
we analysed 7T MRI brain scans of people with MS, which were segmented into cortical lesion, 
WML, and NAWM compartments. Cortical lesions were identified using both MPRAGE and 
magnetisation transfer ratio (MTR) images. WML were detected and NAWM segments were 
defined using MPRAGE images. The extent of damage to NAWM was ascertained by measuring its 
MTR. 
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Results 
 
A single 7T T2*-weighted MRI brain scan was performed at baseline on 29 patients suspected to 
have MS, but in whom initial conventional diagnostic workup proved inconclusive. By calculating 
the proportion of brain lesions containing a central vein on the 7T MRI scan, we were able to 
correctly predict whether the eventual clinical diagnosis arrived at by their treating neurologist was 
MS or not MS (after a median follow-up period of 26 months), in all 22 out of 29 participants who 
had received a clinical diagnosis. 
 
For the cross-sectional study comparing an optimised 3T T2*-weighted MRI brain scan index test 
(against the diagnosis already established by the patient's neurologist), 20 patients were recruited 
for the test cohort. Ten of them had MS and the other 10 patients were known to have 
microangiopathic WML related to small-vessel ischaemic disease (in 7 cases) or migraine (in 3 
cases). The MS group had a significantly higher proportion of lesions with perivenous appearance 
compared to the non-MS group. All MS patients had central veins visible in >45% of brain lesions. 
All non-MS patients had central veins visible in <45% of lesions. Based on this technique, a “rule 
of six” was devised that quickly and accurately characterised MS cases in a further validation 
cohort of another 20 individuals with brain lesions (13 with MS, the rest had WML related to 
hypertension associated small-vessel ischaemic disease or migraine). 
 
In order to assess whether focal multiple sclerosis lesions can be found using 7T MPRAGE MRI in 
NAWM defined using 3T FLAIR MRI, 14 patients with clinically definite MS underwent 3T and 
7T MRI brain scans. Although the majority of lesions were detected both on 3T FLAIR and 7T 
MPRAGE images, 22% of the lesions were only detected using 7T MPRAGE.  
 
To evaluate association between cortical lesions, WML, and diffuse damage to NAWM 19 people 
with MS were recruited to undergo a 7T MRI brain scan. Cortical lesion volume and counts on both 
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MPRAGE and MTR images correlated significantly with NAWM MTR. WML load did not 
correlate significantly with NAWM MTR. 
 
Conclusions 
 
For the cohort of patients in whom conventional methods left initial diagnostic doubt, a single early 
7T T2*-weighted MRI had 100% positive and negative predictive value for MS. 
 
Optimised 3T T2*-weighted MRI can be used to differentiate between individuals with MS and 
those with microangiopathic brain lesions. If validated in a large prospective cohort, this technique 
could complement existing diagnostic algorithms by improving the specificity with which MRI 
demonstrates inflammatory demyelinating brain lesions.  
 
MRI with 7T MPRAGE enables detection of MS lesions in areas defined as NAWM using 3T 
FLAIR MRI. Focal MS lesions contribute to the abnormalities known to exist in what has 
previously been classified as the NAWM. In future, inclusion of 7T MRI lesion maps may refine 
segmentation of NAWM and augment accuracy of analyses involving NAWM metrics.  
 
Cortical lesion load determined using 7T MRI has a significant correlation with NAWM MTR. 
Although it does not prove causation, the correlation implicates cortical lesions in the pathogenesis 
of NAWM injury, which underlies progression and disability in MS. 
 
Keywords: “Multiple Sclerosis”, “Magnetic Resonance Imaging”, “Diagnosis”, “Sensitivity and 
Specificity”  
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Chapter 1: Introduction 
 
The study of multiple sclerosis (MS) began in earnest with the works of Jean-Martin Charcot at the 
Salpétrière in the late 19
th
 century. His influence grew throughout the English-speaking world with 
the publication of the New Sydenham Society edition of his lectures, which consolidated his various 
monikers for the disease into the translation “disseminated sclerosis” (Charcot, 1881). 
 
In the New Sydenham Society translation, Charcot opined that: “Usually, there is superadded a 
whole group of phenomena, which are generally known as cephalic symptoms, and whose starting 
point is a lesion of the cerebral or bulbar nerves, such as the optic nerves, for instance, or the motor 
nerves of the eye. In this relation, we can draw a parallel between progressive locomotor ataxia and 
the disease which I have proposed to call disseminated sclerosis. The latter, like the former, invades 
different points of the cerebro-spinal system simultaneously, and we have cause to discriminate, in 
the clinical description of both affections, between the spinal symptoms and the cephalic symptoms. 
Disseminated sclerosis, like locomotor ataxia, most usually pursues a doomed downward path. But 
the analogies cease there, and, in detailing the symptoms, we have only to mark differences which 
almost always enable us to make a diagnosis without difficulty” (Charcot, 1881). 
 
Since then many advances have been made in the understanding and management of MS, but we 
still recognise the commonest form of the disease principally by its tendency to repeatedly provoke 
distinct episodes of symptoms and signs (i.e. relapses), which are disseminated in time and in space 
(affecting different points of the “cerebro-spinal system”). We still rely on this trait to secure or 
exclude a diagnosis of MS, though now with the assistance of laboratory, neurophysiological, and 
radiological investigations. 
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While relapses disseminated in time and in space are a striking early feature of most cases of MS, 
most individuals with relapsing-remitting MS (RRMS) eventually enter a phase of gradual but 
unrelenting disease progression: secondary progressive MS (SPMS). The mechanisms underlying 
this transition are not fully understood. A minority of people with MS experience unrelenting 
gradual disease progression from the outset, i.e. primary progressive MS (PPMS), sometimes in the 
absence of any relapses. Why this happens in the relative absence of relapses and how PPMS relates 
to RRMS and SPMS is also not fully understood. 
 
My thesis will exploit magnetic resonance imaging (MRI) tools that might supplement existing 
diagnostic techniques for MS, and will also interrogate potential disease mechanisms underlying 
progressive forms of MS. 
 
1.1 Epidemiology of MS 
 
Incidence in the UK is estimated at 2,500 new diagnoses per year, resulting in prevalence of 100 to 
120 cases per 100,000; MS affects twice as many women as men, and incidence peaks in the third 
decade of life (Compston and Confavreux, 2005). 
Prevalence increases with distance from the equator, independent of genetic factors, so that 
prevalence is highest in northern Europe, southern Australia, and North America (Compston and 
Confavreux, 2005). This raises the possibility of environmental aetiological factors including 
infections (Lipton et al., 2007) and vitamin D deficiency due to lack of sun exposure 
(VanAmerongen et al., 2004). Migration modifies risk only among those who migrate early in life; 
those who migrate from low to high prevalence areas after adolescence retain their country of 
origin’s lower risk of developing MS (Alter et al., 1978).  
 
While environmental and genetic factors are contributory, the aetiology of MS remains unknown. 
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1.2 Genetics of MS 
Genetic factors exert a substantial influence: the concordance rate of MS in monozygotic twins is 
30.8%, whereas in dizygotic twins it is 4.7% (Sadovnick et al., 1993). A genome screen in MS 
revealed susceptibility loci on chromosomes 6p21 and 17q22 (Sawcer et al., 1996), but there are 
many genes that seem to be associated with MS including human leucocyte antigen (HLA) classes I 
and II, T-cell receptor β, CTLA4, ICAM1, and SH2D2A (Dyment et al., 2004). 
 
Across the entire human genome, the major histocompatibility complex (MHC) on chromosome 6 
makes the single largest known genetic contribution to MS risk (Patsopoulos et al., 2013). The 
recent advent of high-throughput typing for single-nucleotide polymorphisms (SNP) has enabled 
the study of thousands of individuals, allowing substantial progress to be made in determining 
associations between MS and variation in the genes encoding HLAs contained within the MHC 
(Sawcer et al., 2014). The greatest effect on risk is driven by the HLA-DRB1*15:01 allele, which 
exerts an odds ratio of 3.10 (Sawcer et al., 2011).  
 
Little progress was made in the identification of risk alleles outside the major histocompatibility 
complex before the advent of genome-wide association studies (GWAS). The largest of those 
confirmed 23 previously reported associations and identified an additional 34 new associated 
variants, implicating genes coding for cytokine pathways (CXCR5, IL2RA, IL7R, IL7, IL12RB1, 
IL22RA2, IL12A, IL12B, IRF8, TNFRSF1A, TNFRSF14, TNFSF14), co-stimulation (CD37, 
CD40, CD58, CD80, CD86, CLECL1) and signal transduction (CBLB, GPR65, MALT1, RGS1, 
STAT3, TAGAP, TYK2), as well as genes related to Vitamin D metabolism (CYP27B1, 
CYP24A1) (Sawcer et al., 2011). 
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Fine mapping within the resolution of GWAS signals using the ImmunoChip custom genotyping 
array identified 48 new susceptibility variants, such that there are now 110 established multiple 
sclerosis risk variants at 103 discrete loci outside of the MHC (Beecham et al., 2013). 
 
Meta-analysis of extant GWAS data and use of neoteric methods such as the Exomechip will 
further expand the catalogue of associated variants in the near future. 
 
1.3 Clinical features of MS 
 
Most people with MS have RRMS: discrete episodes of neurological symptoms and disability, 
acute in onset, followed by a period of improvement. Because relapses may affect any part of the 
central nervous system (CNS), diverse symptoms may arise with each relapse. 
 
As Charcot had observed, MS seems to have a predilection for certain areas within the CNS: the 
optic nerves, cerebellum, spinothalamic and pyramidal tracts are commonly involved; giving rise to 
common presenting features of MS such as optic neuritis, ataxia, and sensorimotor disturbances of 
various body parts (Weinshenker et al., 1989). 
 
There is wide inter-individual variability in the frequency and severity of relapses. However, 25 
years after disease onset, 80% of people with RRMS will have transitioned into SPMS (usually 
accompanied by a reduction in relapse frequency) (Kremenchutzky et al., 2006), and 10% to 15% 
of people with MS have PPMS (Thompson et al., 1997; Kremenchutzky, 2003). Mean age of onset 
of PPMS is 38 years (Confavreux et al., 1980; Weinshenker et al., 1989; McDonnell and Hawkins, 
1998; Andersson et al., 1999; Stevenson et al., 1999), similar to the age at which transition from 
RRMS to SPMS tends to occur (Confavreux et al., 2000). 
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1.4 The pathological substrate of clinical disability in MS 
 
Whilst the pathological hallmark of MS is the white matter plaque, axonal loss is the pathological 
process chiefly responsible for irreversible neurological disability in people with MS (Tallantyre, 
Bø, et al., 2010). 
 
The white matter plaque is typically a sharply demarcated ovoid lesion sometimes reaching several 
centimetres in diameter, histopathologically characterised by breakdown of the blood-brain-barrier 
(BBB) and inflammatory cell infiltration (predominantly macrophages, either derived from blood-
borne monocytes, or stemming from resident microglia) effecting demyelination, astroglial scarring, 
and axonal loss (Gay and Esiri, 1991; Kwon and Prineas, 1994; Trapp et al., 1998; Lassmann and 
Wekerle, 2005). 
 
Axonal loss occurs from an early stage in the disease, and is not confined to white matter plaques 
(Trapp et al., 1999; Rovaris et al., 2005; Bjartmar et al., 2001). 
 
Magnetic resonance spectroscopy (MRS) studies confirm that axonal loss, even in the normal 
appearing white matter (NAWM), denoted by reduction in N-acetylaspartate (NAA) levels, is a 
better predictor of clinical disability than conventional MRI lesion load (i.e. white matter plaques) 
(De Stefano et al., 1998; Fu et al., 1998; Lee et al., 2000). 
 
1.5 Treatment of MS 
 
Current therapies are either symptomatic (e.g. to control sensory disturbance, spasticity, sphincter 
dysfunction, fatigue and depression) or “disease modifying therapies” (DMTs). High doses of 
corticosteroids such as methylprednisolone can be used to hasten recovery from a disabling relapse, 
but they do not significantly alter the final extent of recovery (Beck and Cleary, 1993). 
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The Association of British Neurologists (ABN) first published guidelines on the use of licenced 
DMTs in 1999 (at the time licenced DMTs comprised just β-interferon or glatiramer acetate). Their 
guidelines have been periodically updated since, most recently in 2015 (Scolding et al., 2015). 
There is a growing fashion to treat MS earlier and more aggressively in those perceived to have a 
worse outlook, but there is a relative lack of evidence for a long-term benefit from this approach 
(Scolding et al., 2015). Nevertheless, DMTs clearly impact on relapses and relapse-related 
disability, so the ABN recommends initiating treatment as soon as possible in eligible individuals.  
 
All of the licensed DMTs for MS (currently β-interferons, glatiramer acetate, fingolimod, 
teriflunomide, dimethyl fumarate, natalizumab, and alemtuzumab) variably reduce relapse rates and 
lesion accumulation (detected using serial MRI scans) in people with relapsing forms of MS (Rice, 
2014). There are few “head-to-head” comparison trials and inter-trial comparison of drugs is fraught 
with difficulties. Nevertheless, the ABN guidelines divide the DMTs into two classes: those with 
“moderate efficacy” and those with “high efficacy”.  
 
Moderate efficacy drugs (β-interferons, glatiramer acetate, teriflunomide, dimethyl fumarate and 
fingolimod) reduce the average relapse rate by 30% to 50%. High efficacy drugs (alemtuzumab and 
natalizumab) reduce the average relapse rate by substantially more than 50%, but with higher risk of 
potentially serious side effects (Scolding et al., 2015). 
 
Current therapeutic strategies are employed in the hope that reducing relapse rate and MRI lesion 
accumulation might improve long-term prognosis. However, it is quite clear from natural history 
studies that relapse frequency has only a weak correlation with long-term disability (Confavreux et 
al., 2000; Scalfari A et al., 2013).  
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Controlled trials have reported mixed results as to whether β-interferons reduce accumulation of 
disability over 2 to 3 years (The IFNB Multiple Sclerosis Study Group, 1993; Secondary 
Progressive Efficacy Clinical Trial of Recombinant Interferon-beta-1a in MS (SPECTRIMS) Study 
Group, 2001; The North American Study Group on Interferon beta-1b in Secondary Progressive 
MS, 2004). Much of the disability accumulated over a 2 or 3 year period may be directly 
attributable to the effects of relapses, rather than whatever mechanism effects genuine long-term 
disability progression.  
 
There is no controlled trial data available that shows long-term benefit with DMTs; uncontrolled 
studies with follow-up up to 16 years (open-label retrospective analyses of cohorts that were 
originally in 2 or 3 year placebo-controlled β-interferon trials) have conflicting results, with some 
suggesting reduced long-term disability (Bermel et al., 2010), while others do not (Ebers et al., 
2010; Greenberg BM et al., 2013). It is unclear whether high efficacy drugs affect long-term (i.e. 
mean follow-up 6 years) disability (Willis et al., 2015). 
 
It is not clear that any of the currently available DMTs significantly modify progressively 
increasing disability unrelated to relapses, or long-term accumulation of disability, or transition 
from RRMS to SPMS; consequently none of the current DMTs are recommended in non-relapsing 
SPMS or PPMS (Scolding et al., 2015). 
 
1.6 The role of MRI in diagnosis of MS 
Strategies to diagnose MS have necessarily evolved to include the valuable information provided by 
investigational techniques as they have become available. T2-weighted MRI has long been known 
to have excellent sensitivity for the detection of brain white-matter lesions (Young et al., 1981). 
MRI, cerebrospinal fluid (CSF) analysis for oligoclonal bands, and visual and somatosensory 
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evoked potential testing are often invaluable when a diagnosis of MS cannot be achieved based on 
clinical features alone. Even in cases of MS that can be confidently diagnosed on clinical grounds, it 
would now be highly unusual for brain MRI to be omitted in modern Neurological practice. For 
relapsing-remitting MS, when history and examination fail to satisfy diagnostic criteria of 
separation of disease activity in (anatomical) space and time, MRI evidence fulfilling those criteria 
is accepted (Polman et al., 2011). 
 
Positive MRI findings, with or without CSF evidence (on the background of one year of disease 
progression) are formally established as a prerequisite for a diagnosis of primary progressive MS 
(Polman et al., 2011). 
 
Despite their usefulness, none of the above investigations in isolation can claim to demonstrate a 
pathognomonic feature of MS that proves or excludes the diagnosis. Although MRI sequences can 
return signal in brain areas that correlate with areas of inflammation or demyelinated plaques, MRI 
cannot expressly visualise myelin or demyelination. MRI T1 and T2 relaxation times are used to 
generate “scans” showing where (water) proton concentration and physico-chemical environments 
vary. Such changes on MRI scans are not specific for MS, which is why the skill of the neurologist 
will remain in the appropriate clinical evaluation, investigation, and interpretation of results 
according to the prevailing diagnostic criteria, in order to accurately diagnose MS. 
 
1.7 Evolution of diagnostic criteria 
 
In 1983 Poser et al. recommended MS diagnostic criteria based on a gold standard of two or more 
attacks with clinical (with or without supportive “laboratory”) evidence that disease was 
disseminated in space and time. Where clinical evidence was lacking or there was only one attack, 
imaging, neurophysiological findings or oligoclonal bands were allowed to support the diagnosis. 
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By this method Poser stratified diagnoses of MS into one of five groups: 1) clinically definite MS; 
2) clinically probable MS; 3) laboratory supported definite MS; 4) laboratory supported probable 
MS; 5) not MS. These criteria included no formal synthesis on use of MRI changes in MS (Poser et 
al., 1983). 
 
Poser’s criteria did not allow for easy evaluation of people with progressive rather than RRMS. 
Thompson et al. addressed this issue in 2000 by proposing criteria that included findings from MRI, 
CSF, and evoked potentials. For a definite diagnosis of primary progressive MS, they required at 
least one year of clinical progression of disease, along with oligoclonal bands and either definite 
MRI abnormality, or equivocal MRI abnormality plus abnormal evoked potentials. Definite MRI 
abnormality was stipulated as nine or more brain lesions, or two or more spinal cord lesions, or one 
spinal cord lesion plus four to eight brain lesions (Thompson et al., 2000). 
 
In 2001 an international panel led by McDonald devised criteria which specified MRI features that 
would be accepted as demonstration of separation of MS disease activity in space and/or time 
(McDonald et al., 2001). The advantage of this was that earlier secure diagnosis of MS could be 
facilitated by early MRI evidence for separation of MS disease activity in space and/or time, if this 
evidence was lacking clinically. Earlier diagnosis carries with it therapeutic implications and 
potential advantages, since the advent of DMTs. 
 
Under the 2001 international panel “McDonald criteria” for MS: 
• Two or more clinical attacks and objective clinical evidence of two or more 
anatomically separate CNS lesions requires no additional data to confer a diagnosis of 
MS.  
• With two or more clinical attacks but objective clinical evidence of only one lesion, the 
additional data to diagnose MS can be dissemination in space (DIS) demonstrated by 
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MRI, or at least two MRI lesions consistent with MS plus CSF oligoclonal bands, or to 
await a subsequent attack of MS that implicates a different site for the new lesion. 
• With only one attack but objective clinical evidence of two or more lesions, the 
additional data to diagnose MS can be dissemination in time (DIT) demonstrated by 
MRI, or a second clinical attack. 
• With only one attack and objective clinical evidence of only one lesion, such as in a 
clinically isolated syndrome (CIS), the additional data to diagnose MS can be DIS 
demonstrated by MRI, or at least two MRI detected lesions consistent with MS plus CSF 
oligoclonal bands plus DIT demonstrated by MRI, or a second clinical attack. 
• When neurological progression is suggestive of MS but proceeds insidiously, diagnosis 
of (progressive) MS requires positive CSF oligoclonal bands with either: 
o DIS demonstrated by 1) nine or more brain T2 lesions, or 2) two or more lesions in 
the spinal cord, or 3) four to eight brain lesions plus one spinal cord lesion 
or, 
o Abnormal visual evoked potentials (VEP), either with four to eight brain lesions, or 
less than four brain lesions plus one spinal cord lesion on MRI, and 
o DIT demonstrated by MRI 
or, 
o Continued progression for one year 
 
• Meeting three of the following requirements satisfied McDonald et al’s 2001 MRI 
evidence criteria for DIS (based on Barkhof’s criteria (Barkhof et al., 1997) modified by 
Tintoré (Tintore et al., 2000)): 
o One or more gadolinium enhancing lesions, or nine or more T2 hyperintense lesions 
in the absence of gadolinium enhancing lesions 
o One or more infratentorial lesions 
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o One or more juxtacortical lesions 
o Three or more periventricular lesions 
 
• The 2001 criteria laid out two scenarios for establishing MRI evidence for DIT: 
1. If the initial MRI was three months or more after the clinical attack, then the 
presence of a single gadolinium enhancing lesion alone is enough evidence for DIT 
(unless it is at the same anatomical site implicated by the initial clinical attack). If 
there was no enhancing lesion on the original scan, then a follow-up scan is required. 
McDonald et al. recommended that this should probably be done three months after 
the initial scan. On the follow-up scan, a new gadolinium enhancing, or T2 lesion is 
then accepted as sufficient evidence that there was DIT. 
2. If the initial MRI was less than three months after the clinical attack, a follow-up 
scan is required. This should be done after a delay of at least 3 months from the first 
scan. If the second scan shows a new gadolinium enhancing lesion then that is 
sufficient evidence for DIT. If not, then a third scan is required after another delay of 
at least three months. If the third scan shows either a new T2 or gadolinium 
enhancing lesion then DIT is considered evident. 
 
In 2005 the international panel reconvened, led by Polman, and applied revisions to the 2001 
“McDonald criteria” (Polman et al., 2005). The main changes were that: 
• New T2 lesions were now allowed as early evidence for DIT, when there was only a 
single clinical event. 
• Individual spinal cord lesions could now contribute along with individual brain lesions 
to reach the required number of T2 lesions, for DIS. 
• Positive CSF oligoclonal bands were no longer a prerequisite for the diagnosis of 
primary progressive MS. 
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In 2010 the international panel again reconvened, to produce the latest iteration of their diagnostic 
criteria (Polman et al., 2011). The use of MRI for demonstration of dissemination of CNS lesions in 
space and time was simplified, and it became possible for DIS and DIT to be established by a single 
scan: 
• Using these latest 2010 “McDonald Criteria” for Diagnosis of MS, if a patient 
experiences two or more “attacks” (i.e. relapses), and has objective clinical evidence of 
two or more lesions or objective clinical evidence of 1 lesion with reasonable historical 
evidence of a prior attack, no additional data is needed for MS diagnosis. 
• If a patient experiences two or more attacks, with objective clinical evidence of one 
lesion, additional data needed for MS diagnosis is proof of DIS, demonstrated by: 
o One or more T2 lesions in at least 2 of 4 “MS-typical regions” of the CNS (i.e. 
periventricular, juxtacortical, infratentorial, or spinal cord) 
Or, 
o By awaiting a further clinical attack implicating a different CNS site 
• If a patient experiences one attack, with objective clinical evidence of two or more 
lesions, additional data needed for MS diagnosis is proof of DIT, demonstrated by: 
o Simultaneous presence of asymptomatic gadolinium-enhancing and non-enhancing 
lesions at any time  
Or, 
o A new T2 and/or gadolinium-enhancing lesion(s) on follow-up MRI, irrespective of 
its timing with reference to a baseline scan 
Or, 
o By awaiting a second clinical attack. 
• If a patient experiences one attack, with objective clinical evidence of one lesion (i.e. 
CIS), additional data needed for MS diagnosis is proof of DIS and DIT, demonstrated 
by: 
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o (For DIS): 
 One or more T2 lesion(s) in at least 2 of 4 MS-typical regions of the CNS 
(periventricular, juxtacortical, infratentorial, or spinal cord) 
Or, 
 Await a second clinical attack implicating a different CNS site 
o And (for DIT): 
 Simultaneous presence of asymptomatic gadolinium-enhancing and non-
enhancing lesions at any time 
Or, 
 A new T2 and/or gadolinium-enhancing lesion(s) on follow-up MRI, 
irrespective of its timing with reference to a baseline scan 
Or, 
 Await a second clinical attack 
• If a patient experiences insidious neurological progression suggestive of primary 
progressive MS, additional data needed for MS diagnosis is: 
o 1 year of disease progression (retrospectively or prospectively determined) plus 2 out 
of 3 of the following criteria: 
1. Evidence for DIS in the brain based on one or more T2 lesions in the MS-
characteristic (periventricular, juxtacortical, or infratentorial) regions 
2. Evidence for DIS in the spinal cord based on two or more T2 lesions in the 
cord 
3. Positive CSF (isoelectric focusing evidence of oligoclonal bands and/or 
elevated IgG index) 
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The international panel outlined that these latest revisions “simplify the criteria, preserve their 
diagnostic sensitivity and specificity, address their applicability across populations, and may allow 
earlier diagnosis and more uniform and widespread use” (Polman et al., 2011). 
 
1.8 Features distinguishing MS from small vessel ischaemic MRI lesions 
 
Since the inception of MRI as a tool for MS investigation, it has emphasised MS lesions’ 
predilection for the posterior fossa, brainstem, corpus callosum, centrum semiovale, periventricular 
white matter, juxtacortical white matter (subcortical U-fibres) and spinal cord, as well as the optic 
nerves (Ormerod et al., 1987).  
 
The periventricular white matter most frequently involved is adjacent to the trigones and bodies of 
the lateral ventricles (in 96% of clinically definite MS patients’ MRI studies), followed by the white 
matter around the occipital horns (83%), frontal horns (73%), floor of the fourth ventricle (60%), 
and adjacent to the third ventricle (34%) (Ormerod et al., 1987). Infratentorial lesions are more 
commonly in the brainstem (68%) than in the cerebellum (49%) (Ormerod et al., 1987).  
 
From pathology studies it is known that MS plaques frequently involve cortical grey matter (Bø et 
al., 2003), but the sensitivity of MRI in demonstrating these still lags far behind white-matter lesion 
detection sensitivity (Geurts et al., 2005, 2008). 
 
From history and examination it is usually possible to distinguish MS from its commonest 
neuroradiological differential diagnosis, which is cerebral vascular disease giving rise to small 
vessel ischaemic MRI lesions. When there is clinical doubt, morphological differences in MRI 
findings are all the more important. In cerebral vascular disease, areas of MRI signal change can 
vary between large areas attributable to the territory of a major cerebral artery, or small lacunes 
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served by smaller perforating arteries. Changes corresponding to territories of major cerebral 
arteries and peripheral wedge-shaped lesions logically pertain to ischaemic or infarcted tissue. 
Periventricular lesions on MRI due to cerebral vascular disease are typically smooth in outline, 
whereas MS periventricular lesions are typically irregular in outline (Ormerod et al., 1987), 
appearing as finger-like extension of lesions: “Dawson’s fingers” (Dawson, 1916).   
 
In 1965 Fog reported detailed post mortem pathological findings in two people who had MS. He 
showed that out of 43 analysed plaques, 39 followed one or two veins during their course through 
the white matter (Fog, 1965); this suggests that one of the reasons ischaemic lesions differ 
morphologically is because they do not follow the course of a vein, rather they arise at the territory 
supplied by a diseased artery/arteriole.  
 
The predilection for spinal cord involvement in MS is in contrast with ischaemic changes, which 
rarely affect the cord (Kidd et al., 1993; Thorpe et al., 1993). Fog also demonstrated that spinal cord 
MS plaques follow the path of radicular veins in the cord’s white matter tracts, though this does not 
necessarily determine the eventual form of the plaque in the cord (Fog, 1950). 
 
Certain MRI techniques can be useful in distinguishing MS and ischaemia, irrespective of lesion 
topography and morphology. Gadolinium is used as a contrast agent because the gadolinium moiety 
has several unpaired electrons, which has the effect of markedly reducing T1 relaxation times for 
neighbouring water protons, thus generating T1-hyperintensity wherever gadolinium enters tissues. 
Gadolinium transudes only from vessels that have developed a leaky blood-brain-barrier, usually 
due to inflammation as found in active MS plaques; enhancement typically lasts 4 to 6 weeks 
(Miller et al., 1988). Although gadolinium contrast-enhancing lesions are less frequent than T2 or 
FLAIR hyperintensities in MS, they can distinguish MS from ischaemic lesions, which do not 
enhance. The caveat is that other processes such as malignancy and granulomatous disease can also 
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enhance. Contrast enhancing lesions and juxtacortical lesions are highly predictive that 
monosymptomatic disease will progress to MS (Barkhof et al., 1997). 
 
Chronic T2-hyperintense lesions in MS are more likely to show T1-hypointensity (“black holes”) 
when compared with T2-hyperintensities caused by other pathologies such as small vessel 
ischaemic change. Chronically T1-hypointense lesions are associated with worse axonal loss than 
T1-isointense (but T2-hyperintense) lesions. Not all T1-hypointensities are chronic; they can be a 
transient finding (resolving over several months) in gadolinium enhancing lesions (Uhlenbrock and 
Sehlen, 1989). 
  
Diffusion weighted imaging (DWI) typically shows “restricted diffusion”, i.e. reduced apparent 
diffusion coefficient (ADC) values in acute infarcts (though its utility in distinguishing old infarcts 
is poor). In MS plaques there is typically an increase in ADC value, and the diffusion change when 
compared to NAWM is more marked than changes in T2 signal intensity (Larsson et al., 1992). 
However, it has also been reported that new contrast-enhancing MS lesions can initially show 
reduced ADC which subsequently converts to increased ADC, coinciding with the development of 
the peripheral vasogenic oedema seen as hyperintensity on T2-weighted images (Balashov et al., 
2011). Diffusion tensor imaging has shown value in detection and also quantification of tissue 
damage, both inside and outside of T2-intense MS lesions (Rovaris and Filippi, 2007).  
 
Perfusion-weighted MRI mean transit time (MTT) values are more prolonged in acute and chronic 
stroke lesions and their surrounding NAWM, when compared to acute and chronic MS plaques 
(Zivadinov et al., 2008). 
 
Magnetisation transfer imaging (MTI) unveils the relative concentration of immobile protons 
closely associated with macromolecules such as myelin. In the CNS, reduction in magnetisation 
35 
 
transfer ratio (MTR) indicates relative reduction of macromolecular structure i.e. axons and their 
myelin, or an increase in the availability of mobile water protons e.g. due to inflammation and 
oedema (Mac Innes and Arnold, 2004). MTR is significantly different in MS plaques and cerebral 
ischaemic infarcts, and has been shown to distinguish between the two; however reduced MTR is 
not specific to MS plaques, and does not distinguish vasogenic oedema from subacute cerebral 
ischaemic infarcts (Reidel et al., 2003). 
 
Although MRS has had numerous reported applications in MS (and shows great promise as an 
advanced outcome measure), its diagnostic utility in distinguishing MS from ischaemic lesions 
requires further study (Gonzalez-Toledo et al., 2006). 
 
In summary, morphological and topographical indicators are currently the core features in assessing 
whether MRI lesions represent plaques of demyelination, or whether they are not demyelination 
(typically ischaemic areas). Advanced MRI techniques show some promise, but none as yet can be 
considered to show a feature pathognomonic for MS. 
 
1.9 Ultra-high field MRI 
 
By using ultra-high magnetic field strengths such as 7T, MRI systems can achieve a higher signal to 
noise ratio (SNR), because SNR increases linearly with the magnitude of the main magnetic field 
(B0) (Uğurbil et al., 2003; Duyn, 2012). This increase in SNR may be used to attain increased 
spatial resolution, or more rapid image acquisition (or some intermediate combination of the two). 
 
Ultra-high magnetic fields also afford enhanced contrast mechanisms: improved imaging of non-
proton nuclei such as sodium and phosphorus; greater spectral separation of metabolites in MRS; 
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and increased blood oxygen level–dependent (BOLD) contrast for higher resolution functional MRI 
(Balchandani and Naidich, 2014).  
 
The improvement in BOLD contrast comes from augmented T2* dephasing around deoxygenated 
blood (Sanchez-Panchuelo et al., 2012). Correspondingly, MRI sensitivity to susceptibility effects 
scales with field strength, improving the visibility of venous microvasculature (as well as 
microbleeds, and iron or calcium deposits) using susceptibility-weighted imaging (SWI) (Haacke et 
al., 2009). 
 
There are technical and physical limitations to the use of ultra-high field MRI. These include 
inhomogeneity of both B0 and the applied radiofrequency (RF) field (B1), errors in chemical shift 
localisation, and increased deposition of RF power within the patient (measured as the specific 
absorption rate (SAR), which increases as the square of B0) (Balchandani and Naidich, 2014).  
 
B0 inhomogeneity directly scales with field strength, and as the B0 field increases to 7T, the 
requisite RF wavelength becomes comparable with the diameter of the human head, resulting in a 
reduction of B1 strength in the brain periphery compared with the centre, causing signal drop-out 
and unexpected changes in contrast (Vaughan et al., 2001). These limitations cause image artefacts, 
limit section number and spatial coverage, and complicate the use of MRI and MRS at 7T. 
 
Notwithstanding these limitations, advantages inherent to ultra-high field MRI ought to be exploited 
in order to improve understanding and management of neurological disease. If one looks through a 
different lens, one gets a different view. For diseases that are incompletely understood, a different 
view may be a boon. 
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Chapter 2: Ultra-High Field MRI Provides A Pathologically Specific Diagnostic 
Biomarker For Inflammatory Demyelination In The Brain 
 
2.1 Introduction 
 
Diagnosis of multiple sclerosis (MS) is based on demonstrating dissemination of central nervous 
system (CNS) lesions in space and time using a combination of clinical and investigative methods. 
At present, there is no single test that is diagnostic for multiple sclerosis, including magnetic 
resonance imaging (MRI). Brain white matter lesions are readily detected with MRI; however, most 
MRI techniques lack histopathological specificity.  As a result, other conditions can produce MRI 
appearances which mimic those of MS (Rolak and Fleming, 2007). White matter lesions caused by 
small-vessel ischaemic changes related to ageing, cerebrovascular disease or migraine can cause 
diagnostic difficulties (Pretorius and Quaghebeur, 2003). Fortunately, the clinical history and the 
anatomical location and shape of the white matter lesions usually allow differentiation of MS from 
other conditions (Fazekas et al., 1999). In the right clinical scenario, MRI can demonstrate 
dissemination in space (DIS) and dissemination in time (DIT) and permit an MS diagnosis 
according to the 2010 revisions to the criteria of the International Panel on Diagnosis of MS 
(Polman et al., 2011). Clinical assessment and other paraclinical tests incorporated in the criteria 
counteract the inherent lack of specificity with which MRI depicts MS lesions.   
 
In a significant minority of cases however, diagnosing MS can be challenging, especially in the 
early stages, in late-onset disease, and in the absence of typical history. This is a problem mainly 
encountered in MS referral centres. The International Panel stipulates  that their criteria for MS 
diagnosis should be applied only when patients have experienced a typical clinically isolated 
syndrome (CIS) (or progressive paraparesis, cerebellar, or cognitive syndrome in the case of 
suspected primary progressive MS (PPMS)), thereby reinforcing specificity by improving “pre-test” 
probability of eventual MS. The presence of cerebrospinal fluid (CSF) oligoclonal bands (OCB) at 
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the time of initial presentation cannot always be relied upon; study results vary widely, but only 
46% to 75% of newly presenting patients have OCBs (Tintoré et al., 2008), and OCBs can be 
present in conditions other than MS (Rolak and Fleming, 2007). If MRI could have enhanced 
histopathological specificity for white matter lesions, future diagnostic criteria for MS could be 
simplified. 
 
Many neurologists consider early  treatment of MS, and even following a CIS, to be beneficial 
(Jacobs et al., 2000; Comi et al., 2001; Kappos et al., 2007). Despite this, initial misdiagnosis, long 
referral delays, and long diagnostic delays are widespread (Levin et al., 2003; Kingwell et al., 
2010).  
 
The histopathological precedent that most MS lesions are centred on a vein was elegantly 
demonstrated long ago (Fog, 1964), and is consistent with the hypothesis that auto-reactive T-cells 
enter brain parenchyma from the systemic circulation and induce local destruction of myelin. Of all 
pathological features that define CNS demyelinating diseases and distinguish them from other 
predominantly white matter diseases, the perivenous demyelination identified by microscopy is the 
most specific (Greenfield, 2008). Standard T2-weighted 1.5T brain MRI in conjunction with 
additional susceptibility weighted imaging (SWI) MR venography has previously been used to 
show the relationship between MS lesions and blood vessels (Tan et al., 2000). While this 
technique can demonstrate a MS lesion and a blood vessel in close proximity, its failure to 
demonstrate them simultaneously using a single image acquisition makes exact spatial relationships 
difficult to determine. 
 
Ultra-high field in vivo MRI can be used to provide enhanced spatial resolution and strong T2* 
contrast (due to the paramagnetic properties of deoxyhaemoglobin, veins become especially 
hypointense in T2*-weighted images). Ultra-high field strength, i.e. 7T T2*-weighted MRI has 
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previously been used to demonstrate central veins in the majority of lesions in people known to 
have MS (Tallantyre et al., 2008), and is superior to SWI for demonstrating relevant sizes of veins 
in varying orientations (Dixon et al., 2011). Applying the same 7T MRI technique has been shown 
to accurately distinguish people known to have MS (in whom >40% lesions appeared to have 
central veins) from people known to have ischaemic (i.e. microangiopathic) incidental white matter 
MRI hyperintensities (in whom <40% lesions appeared to have central veins) (Tallantyre et al., 
2011). 
 
The real usefulness of a diagnostic biomarker depends on its accuracy at the time of the patient’s 
initial presentation, rather than its ability to distinguish established cases of MS from established 
cases without MS. The present study aimed to prospectively assess the value of a single 7T T2*-
weighted MRI brain scan for predicting an eventual diagnosis of MS in patients in whom the 
question of inflammatory demyelination has been raised, but diagnosis could not initially be 
reached despite experienced clinical and radiological assessment.   
 
2.2 Patients and methods 
2.2.1 Study design 
 
This was a longitudinal cohort study comparing the diagnostic utility of an index test (performed at 
baseline) against the reference standard after follow-up.  
 
The index test was based on a single T2*-weighted 7T MRI brain scan performed and analysed in 
advance of any further investigations arranged by the treating neurologists.  
 
The reference standard was the eventual diagnosis arrived at by treating neurologists (Dr Evangelou 
and his consultant colleagues) with specialist interest in MS blinded to results from the 7T MRI 
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analysis. The diagnosis, as is standard practice, was reached by using the clinical history and 
examination and paraclinical tests in accordance with the criteria of the International Panel on 
Diagnosis of MS available at the time.  
 
2.2.2 Participants 
 
Patients referred to the Neurology department of Nottingham University Hospitals NHS Trust were 
considered for enrolment in this study if a neurologist specialising in MS was unable to diagnose 
MS or not MS without further paraclinical testing and/or clinical follow-up. Participants prior to 
enrolment had at least one clinical brain MRI of satisfactory diagnostic quality, interpreted by an 
experienced neuroradiologist with whom the treating neurologist had discussed the clinical details. 
Patients were recruited by Dr Evangelou. 
 
Recruited patients comprised two groups. The first group were those who had experienced a typical 
CIS (or sustained deterioration consistent with progressive MS), but had MRI findings inconsistent 
with or insufficient to support a diagnosis of MS. The second group comprised people with 
neurological presentations not conforming to typical CIS (or sustained deterioration consistent with 
progressive MS), in whom subsequent MRI appearances raised neuroradiological suspicions of 
demyelinating disease. The study population was a consecutive series of participants defined by the 
inclusion and exclusion criteria prospectively enrolled before the index test (7T MRI scan) was 
performed. After the index test, patients were followed-up prospectively to allow for the reference 
standard of clinical diagnosis to be achieved, by the accrual of further clinical events and/or 
additional clinical investigations. 
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Potential participants were excluded if they did not wish to undergo an additional research MRI 
scan. All subjects gave informed consent and the study had been approved by the local research 
ethics committee. 
 
2.2.3 Image acquisition 
 
Images were acquired using a Philips Achieva 7T system (Philips Medical Systems, Best, The 
Netherlands) equipped with whole-body gradients, a 16-channel head-only parallel imaging SENSE 
receive coil and a head-only volume transmit coil (Nova Medical, Inc., Wilmington MA, USA). 
The scanner console was operated by Dr Dixon, with Dr Mistry present in all cases. A 3-
dimensional gradient echo sequence was acquired using 200 transverse slices acquired in 4 stacks, 
each stack overlapping by 10 slices (192 X 164 X 85 mm3 field of view, 0.5 mm isotropic voxels, 
echo time = 20 ms, repetition time = 150 ms, and flip angle 14°). A parallel imaging SENSE factor 
of 2 (right–left direction) and an EPI factor of 3 were employed; acquisition time was 8.8 minutes. 
 
2.2.4 Data analysis 
 
Dr Mistry analysed the anonymised MRI data, blinded to all clinical information and guided by an 
experienced neuroradiologist (Dr Jaspan).  
 
Analysis was restricted to the supratentorial brain volume because at the time of this study, the 7T 
receive coil array yielded suboptimal SNR infratentorially. Lesions were classed as perivenous if 
they appeared to have one or more central veins. On 7T images a central vein was considered to be 
present if its hypointensity appeared at the centre of the surrounding hyperintense lesion in at least 
two out of three orthogonal planes.   
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A perivenous lesion percentage “cut-off” of 40% was chosen to predict a diagnosis of MS (>40%) 
or non-MS (<40%) based on the findings of previous work (Tallantyre et al., 2011).  
 
2.2.5 Statistical methods 
 
Dr Tench devised the statistical methodology which was applied by Dr Mistry. Fisher’s exact test 
was used to compare the proportion of perivenous lesions and the occurrence rate of specific vein-
lesion morphologies in the MS vs. the non-MS groups. We estimated accuracy of the index test by 
calculating the proportion of agreement with the reference standard.  
 
Although data was anonymised there was potential for un-blinding according to whether lesions had 
an anatomical distribution characteristic for MS. To assess lesion vein classification reproducibility 
and determine whether lesion classification had been influenced by such un-blinding, tightly 
cropped images of randomly selected lesions (without anatomical context or orientation 
information) were classified according to perivenous status by a second observer (Dr Abdel-Fahim) 
who was blinded to the original results. This was done for 20 lesions seen in three orthogonal 
planes. Cohen kappa coefficient of agreement between the two observers was calculated by Dr 
Mistry.  
 
2.3 Results 
2.3.1 Participants 
 
Twenty nine patients were recruited between 13 May 2009 and 10 February 2012; comprising 21 
females and 8 males, whose median age was 50.7 years (range 30.6 to 74.5). Each individual’s 
demographic data is listed in table 2.1. All participants underwent the index test.  Seven have not 
yet received a clinical diagnosis from their neurologist. This is summarised in figure 2.1. The 
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median follow-up period (since the index test) was 26 months (range 4 to 37 months). None of the 
patients received disease modification therapies during the study period. All those eventually 
diagnosed with MS had minimal or no disability. 
 
2.3.2 Test results 
 
Of the 22 participants with a clinical diagnosis, 13 were diagnosed with MS and 9 were diagnosed 
with microangiopathic white matter lesions. All 13 patients with an eventual diagnosis of MS had 
central veins visible in >40% of brain lesions (median 97%, range 70% to 100%). All 9 patients 
with an eventual non-MS diagnosis had central veins visible in <40% of lesions (median 25%, 
range 9% to 33%; figure 2.2). This difference between the proportion of perivenous lesions in the 
MS versus non-MS group was highly significant (p<0.0001). Example lesions from each group are 
shown in figure 2.3.  Lesions in MS diagnosed patients often had characteristic morphology when 
seen using 7T T2*-weighted MRI, as shown in figure 2.4. Cross-tabulation of the 7T index test 
results vs. clinical MRI findings and paraclinical test data at the time of recruitment is shown in 
table 2.1. 
 
One subject’s 7T brain scan was of poor quality due to movement artefact which obscured the 
visibility of small veins, rendering the scan uninterpretable. 
 
In the MS group the total lesion count was 181 (of which 159 were perivenous) and median lesion 
volume was 36.0mm
3
 (range 1.9mm
3
 to 5500.5mm
3
).The MS group had a median of 10 lesions per 
scan (range 5 to 32). In the non-MS group the total lesion count was 165 (of which 35 were 
perivenous) and median lesion volume was 10.8mm
3
 (range 0.3mm
3
 to 807.7mm
3
). The non-MS 
group had a median of 16 lesions per scan (range 10 to 35). 
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There were no adverse events associated with the index test and none documented pertaining to the 
reference standard. 
 
For 7T lesion vein classification, inter-rater agreement was perfect (Cohen kappa coefficient = 
1.000, SE of kappa = 0.000), suggesting excellent reproducibility and that un-blinding based on 
perceived anatomical pattern of lesions had not influenced the primary observer’s classification. 
 
2.4 Discussion 
 
In this prospective study we found that a single 7T T2*-weighted MRI scan can be used to 
accurately diagnose inflammatory demyelination and predict MS at follow up.  The number of 
individuals enrolled in this study was small, and further follow-up of this preliminary study’s cohort 
will be required to corroborate eventual diagnoses, due to the limitations of the reference standard. 
In reality, the definite diagnosis is sometimes only established after years, and currently only expert 
histopathological examination can be truly definitive.  If confirmed in a large prospective cohort 
using 3T clinical scanners in multiple centres, the diagnosis of inflammatory demyelination and MS 
could be simplified.   
 
The conventional MRI characteristics of MS lesions are non-specific. For this reason, the 
International Panel’s 2010 MS diagnostic criteria only apply in cases with typical CIS (or a year of 
sustained progression for PPMS) and cannot be used for white matter lesions found incidentally, 
when the MRI was performed for another indication.  Even in the context of a typical CIS, existing 
diagnostic MRI criteria for dissemination in space are imperfect (sensitivity of 71.9% and a 
specificity of 77.2%) (Díaz-Sánchez et al., 2010). In cases without a typical CIS history, or with 
non-typical MRI findings, diagnostic dilemma and delay can impact on patients’ emotional 
wellbeing, as well as diverting further resources into additional tests and clinical assessments. 
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Patients commonly find lumbar puncture to be an unpleasant experience, and it is often 
diagnostically unhelpful. CNS tissue biopsy has been the only specific way to identify 
demyelinating plaques in vivo. T2*-weighted MRI enables simultaneous visualisation of 
hyperintense MS lesions and their central veins, which appear contrastingly hypointense due to the 
paramagnetic properties of deoxyhaemoglobin. Along with visual evoked potential testing (VEP), 
this could form the basis for another non-invasive pathologically specific single in vivo test for 
detecting inflammatory demyelinating CNS plaques, which (in common with VEP) seems able to 
distinguish MS from neuromyelitis optica (NMO) (Kister et al., 2013; Neto et al., 2013). Even so, it 
has not been tested for distinguishing MS from other rarer causes of inflammatory demyelination; 
therefore clinical acumen and appropriate paraclinical testing would still be required in order to 
distinguish other causes (such as acute disseminated encephalomyelitis) from MS. 
 
In our cohort, using 7T T2*-weighted MRI analysis to dichotomise patients (according to whether 
more or less than 40% of their lesions were perivenous) was a reliable way to predict eventual 
clinical diagnosis, with 100% positive and negative predictive value for MS.  
 
This cohort’s median age of almost 51 years differs from the usual presentation of MS: typically a 
patient in her 20s (Coles, 2009). This difference seems a product of the inclusion criteria, 
suggesting that in our centre difficult to diagnose patients were more likely to be older (perhaps due 
to greater likelihood of coincidental small-vessel ischaemic lesions). This raises issues regarding the 
generalisability of our findings. Limiting inclusion to younger patients could have limited this 
study’s generalisability to older patients who may be referred to clinic with diagnostic difficulty. 
Seven of the patients included in this study were in their 30s, of whom 6 received a clinical 
diagnosis. Reassuringly, in all 6 of those cases the index test’s positive and negative predictive 
value for MS was maintained (table 2.1). However, future larger studies with analysis subdivided 
by age will be required to prove whether the predictive value really persists across age groups. 
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The visibility of small veins is impaired if the image signal to noise ratio is poor, for example when 
movement artefact degrades image quality. Interpretation of images degraded by movement could 
result in false negatives. In this study, only one attempt was made to acquire a T2*-weighted scan 
for each participant. Were such a technique to be used clinically in the future, image acquisition 
could be reattempted in the event of poor initial scan quality.  
 
To conclude, for the current cohort of patients in whom conventional methods left initial diagnostic 
doubt, a single early T2*-weighted 7T MRI had 100% positive and negative predictive value for 
MS. 
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Figures and tables 
Figure 2.1 Flow diagram summarising 7T study design 
All participants underwent the index test which was a single 7T MRI brain scan. The 7T MRI result 
was positive if >40% of visible brain lesions appeared perivenous, and negative if <40% of visible 
brain lesions appeared perivenous. The reference standard was clinical diagnosis, i.e. the eventual 
diagnosis arrived at by the treating neurologist with specialist interest in MS. In one participant the 
7T brain scan could not be interpreted as it was degraded by movement artefact. The reference 
standard has so far been inconclusive in 7 of the participants, who remain under clinical follow-up. 
CIS = clinically isolated syndrome; 7T = 7 Tesla; MRI = magnetic resonance imaging; MS = 
multiple sclerosis. 
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Figure 2.2 Distribution of 7T MRI index test results according to reference standard 
Eventual diagnosis could be dichotomised into MS or not, according to whether the percentage of 
perivenous lesions was above or below 40%. 
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Figure 2.3 Examples of lesions detected using 7T MRI 
7T T2*-weighted MRI. Panel A shows a lesion from a patient diagnosed with MS, which appears to 
have a vein coursing through it. Panel B shows a microangiopathic lesion from a patient diagnosed 
as not having MS; contrastingly this lesion does not have a vein passing through its centre. 
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Figure 2.4 Characteristic 7T MRI MS lesion morphologies 
7T T2*-weighted MRI. Panel A shows a sagittal view of a periventricular lesion with a “Dawson’s 
finger” appearance. Deep white matter lesions are shown in panels B (axial view) and C (coronal 
view), with a “donut” appearance in B, and a “coffee bean” appearance in C. 
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Table 2.1 Cross tabulation of results from 7T index test and reference standard with 
summary of clinical MRI scans available at the time of inclusion in the 7T MRI study 
 
The 7T MRI index test was considered positive if >40% of lesions were perivenous. All patients 
with an eventual diagnosis of MS had a high percentage of perivenous lesions on 7T MRI, and vice-
versa. The clinical FLAIR and T2-weighted spin-echo MRI images available at baseline were 
assessed for dissemination in space (DIS) and dissemination in time (DIT) of visible white matter 
lesions according to the 2010 diagnostic criteria for MS. It must be noted that those diagnostic 
criteria are not to be used in the absence of a typical clinically isolated syndrome (CIS) (*or one 
year of progressive paraparesis, cerebellar, or cognitive syndrome in the case of suspected primary 
progressive MS); therefore DIS and DIT assessments listed in absence of CIS have the caveat that 
they could not have been used diagnostically. For those with a non-MS diagnosis, risk factors for 
small vessel ischemic lesions are given in brackets. 
I.T. = index test; R.S. = reference standard; M.S.A. = multiple system atrophy; F.M.F. = familial 
Mediterranean fever; N/A = not available. 
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Perivenous 
lesions %  
Eventual Diagnosis  
Age 
(years) 
Sex 
I.T. to 
R.S. 
Interval 
(years) 
Current 
follow-up 
(months) 
Oligoclonal 
Bands  
Evoked 
potentials  
Clinical 
head 
MRIs  
Clinical 
spine 
MRIs  
Gadolinium 
contrast 
DIS DIT  
Typical 
CIS* 
(Index test)  (Reference Standard)  
100 Multiple sclerosis 54.8 F 0.13 29.59 Positive Positive 1 1 NO NO NO YES 
100 Multiple sclerosis 36.7 F 0.42 24.93 N/A N/A 1 1 NO YES NO YES 
100 Multiple sclerosis 36.3 F 0.27 33.05 Positive Positive 1 1 NO NO NO NO 
100 Multiple sclerosis 30.8 F 0.32 30.09 Positive N/A N/A N/A N/A N/A N/A NO 
100 Multiple sclerosis 41.4 M 0.06 24.96 Positive N/A 2 2 YES NO NO NO 
100 Multiple sclerosis 30.6 F 1.11 31.57 Positive N/A 4 1 YES YES YES YES 
97 Multiple sclerosis 63.4 M 0.02 38.54 Negative N/A 1 1 NO YES NO NO 
92 Multiple sclerosis 45.1 M 0.12 38.34 N/A N/A N/A N/A N/A N/A N/A NO 
92 No diagnosis yet 52.5 M 2.29 27.46 Negative N/A 2 1 NO YES NO YES 
91 Multiple sclerosis 59.0 F 0.33 22.66 N/A N/A 2 0 NO YES NO YES 
90 Multiple sclerosis 61.3 F 1.04 36.93 Positive Positive 2 3 YES NO YES YES 
85 No diagnosis yet 69.1 F 1.95 23.39 Negative N/A 1 1 NO YES NO YES 
84 No diagnosis yet 67.6 M 0.46 5.57 Negative N/A 1 1 NO NO NO YES 
82 No diagnosis yet 48.0 F 2.99 35.84 Negative N/A N/A N/A N/A N/A N/A NO 
77 Multiple sclerosis 59.6 F 0.3 33.31 Positive N/A 1 0 NO NO NO NO 
70 Multiple sclerosis 74.5 M 0.16 23.55 Negative N/A 1 1 NO YES NO YES 
70 Multiple sclerosis 53.8 F 0.11 27.46 Positive N/A 2 1 YES YES YES YES 
33 Migraine 50.4 F 0.32 23.39 Negative Negative 2 3 NO YES NO NO 
31 M.S.A. (smoker) 72.4 F 0.95 23.16 N/A N/A 3 0 YES YES NO NO 
30 Antiphospholipid syndrome 60.8 F 0.41 11.18 Positive N/A N/A N/A N/A N/A N/A NO 
30 No diagnosis yet 38.6 F 0.46 5.57 N/A N/A 1 1 NO NO NO YES 
29 Functional disorder (migraineur) 40.5 F 0.33 27.49 Negative Negative 1 1 NO YES NO NO 
25 Stroke (smoker, hypertension) 50.7 M 0.17 35.32 Negative N/A 2 0 NO YES NO YES 
19 No diagnosis yet 46.1 F 1.96 23.55 Negative N/A 1 0 NO YES NO NO 
11 Migraine 31.6 F 1.31 33.05 N/A N/A 2 1 NO NO NO NO 
11 Glioma (hypercholersterolaemia) 64.4 F 0.22 7.7 Positive N/A 1 0 YES NO NO NO 
10 Stroke (smoker) 41.0 F 0.82 35.32 Negative Negative 1 0 NO NO NO YES 
9 F.M.F. (smoker) 36.5 F 0.91 36.93 Negative N/A N/A N/A N/A N/A N/A NO 
Uninterpretable No diagnosis yet 55.7 M 2.47 29.59 N/A N/A 1 0 NO YES NO NO 
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Chapter 3: Central Veins In Brain Lesions Visualized With 3 Tesla Magnetic 
Resonance Imaging: A Clinically Applicable Diagnostic Biomarker For 
Inflammatory Demyelination In The Brain 
 
3.1 Introduction 
Using current diagnostic criteria, confirming a diagnosis of MS is relatively straightforward in most 
cases. However, in a significant minority of patients posing diagnostic difficulties, pathologically 
specific imaging of brain lesions could expedite accurate diagnosis, reduce the anxiety of non-
diagnosis, and facilitate earlier intervention using current or emerging treatments, when appropriate. 
 
Ultra-high field strength 7T T2*-weighted magnetic resonance imaging (MRI) has been used to 
demonstrate central veins in the majority of white matter lesions in people known to have MS 
(Tallantyre et al., 2008). The same 7T MRI technique can reliably distinguish people known to have 
MS from those known to have small vessel ischaemia (Tallantyre et al., 2011), and can  accurately 
predict which patients who have brain white matter lesions but diagnostic uncertainty will develop 
MS (Mistry et al., 2013). 
 
The relevance of this diagnostic approach depends on its translation to clinically available MRI 
scanners. Although the perivenous distribution of MS lesions has been shown by many groups 
using 7T MRI (Tallantyre et al., 2008; Kollia et al., 2009), 3T MRI studies investigating whether 
perivenous visualisation of lesions characterises MS have given conflicting results (Lummel et al., 
2011; Tallantyre, Morgan, et al., 2009). However, optimised 3T T2*-weighted MRI techniques 
have yielded encouraging initial results (Dixon et al., 2011). We aimed to assess the effectiveness 
of a single 3T T2*-weighted MRI brain scan in distinguishing between people known to have MS, 
and people known to have microangiopathic brain lesions.  
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3.2 Patients and methods 
3.2.1 Study design 
 
This was a cross-sectional study comparing the index test, which was based on a single T2*-
weighted 3T MRI brain scan, against the reference standard, which was the diagnosis already 
established by the patient's neurologist.  
 
3.2.2 Participants 
 
Dr Evangelou, Dr Mistry and Dr Samaraweera recruited patients from the Neurology outpatients 
department of Nottingham University Hospitals NHS Trust. For inclusion in the study, MS patients 
had to have a diagnosis of MS already established or confirmed by a tertiary centre neurologist 
specialising in MS, in conjunction with expert neuroradiological interpretation of pre-existing MRI 
scans, in accordance with the current criteria from the International Panel on MS Diagnosis. 
Disability was assessed in clinic by the patient’s treating physician using EDSS (Kurtzke, 1983). 
Control subjects had to have brain white matter lesions on pre-existing MRI scans, diagnosed by 
neurologist and neuroradiologist in consensus as due to small vessel ischaemia. All subjects gave 
informed consent and the study had been approved by the local research ethics committee. The first 
20 patients formed a test cohort. A further 20 patients were recruited and scanned to form a 
validation cohort.  
 
3.2.3 Image acquisition 
 
Each participant underwent a T2*-weighted 3T MRI brain scan using an Achieva 3T system 
(Philips Medical Systems, Best, The Netherlands) with a 32-channel parallel imaging head receive 
coil. Dr Dixon operated the scanner console with Dr Mistry or Dr Samaraweera present in all cases. 
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A 3-dimensional gradient echo sequence was acquired using 96 transverse slices acquired in 4 
interleaved axial stacks, each stack overlapping by 3 slices (220 x 186 x 95.2 mm
3
 field of view, 
voxel dimensions 0.55 x 0.55 x 1.05 mm
3
, angulation to B0 = 0°, echo time = 25 ms, repetition time 
= 150 ms, flip angle = 14°, parallel imaging factor of 2 (right-left direction), EPI factor of 3); 
acquisition time was 8.6 minutes. 
 
3.2.4 Data analysis 
 
Dr Mistry analysed the anonymised MRI data, blinded to all clinical information guided by an 
experienced neuroradiologist (Dr Jaspan). Each white matter lesion visible on the T2*-weighted 
image was assessed for the presence or absence of a central vein. A central vein was considered to 
be present if its hypointensity appeared at the centre of the surrounding hyperintense lesion. 
Confluent lesions were included; each was counted as a single lesion for the purpose of this study. 
Confluent lesions are more likely to straddle a vein (regardless of aetiology), and large ones may 
contain several veins, especially in periventricular white matter; they were classed as perivenous if 
there was a central vein (e.g. in a lesion with 3 vessels, as long as one was "central", it was classed 
as perivenous).  
 
As Virchow-Robin spaces could be seen as linear hyperintense streaks, sometimes up to 4 voxels in 
thickness (i.e. approximately 2mm), hyperintensities were not considered "lesions" unless they 
exceeded 4 voxels in their shortest dimension, in order to avoid false positives. Every white matter 
lesion exceeding 4 voxels in its shortest dimension was included in the study and evaluated for the 
presence of a vessel in the test cohort. 
 
3.2.5 Diagnostic rules and validation 
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Clinical application of this technique requires a method which is practical; calculating the 
proportion of perivenous lesions based on the total lesion load is laborious and time consuming. 
However, within the test cohort, small perivenous MS lesions centred on a single vein were 
frequently seen to exhibit stereotypical morphology: when the MRI slice was along the vein’s axis, 
lesions assumed a “coffee bean” appearance (or a “Dawson’s finger” appearance if the vein 
projected perpendicularly from the ventricular border), and when the MRI slice was more 
perpendicular to the vein they had a ring or “donut” appearance (figures 3.1 and 3.2). Using these 
features Dr Mistry devised simple rules, so that an observer could rapidly allocate 3T T2*-weighted 
scans into the correct disease category. These rules are: 
1. If there are 6 or more morphologically characteristic lesions the diagnosis is inflammatory 
demyelination. 
2. If there are fewer than 6 morphologically characteristic lesions, but morphologically 
characteristic lesions outnumber non-perivenous lesions, the diagnosis is inflammatory 
demyelination. 
3. If neither of these conditions is met, inflammatory demyelination should not be diagnosed. 
These diagnostic rules were used on the validation cohort by Dr Mistry.  
 
3.2.6 Statistical methods 
 
Dr Tench devised the statistical methodology which was applied by Dr Mistry. Fisher’s exact test 
was used to compare the proportion of perivenous lesions and the occurrence rate of specific vein-
lesion morphologies in the MS vs. the non-MS groups. We estimated accuracy of the index test by 
calculating the proportion of agreement with the reference standard.  
 
Although data was anonymised there was potential for un-blinding according to whether lesions had 
an anatomical distribution characteristic for MS. To assess the reproducibility of identifying veins 
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and determine whether results had been influenced by such un-blinding, tightly cropped images of 
randomly selected lesions (without anatomical context or orientation information) were classified 
according to perivenous status by a second observer (Dr Abdel-Fahim) who was blinded to the 
original results. This was done for 20 lesions and a Cohen kappa coefficient of agreement between 
the two observers was calculated by Dr Mistry. 
 
3.3 Results 
3.3.1 Participants 
 
For the test cohort, 20 patients were recruited: 10 of them had MS (comprising 4 females and 6 
males, median age 50 years (range 35 to 66)). Their median EDSS was 3.5 (range 0 to 7.5), 7 of 
them had relapsing-remitting MS, 2 had secondary progressive MS, and 1 had primary progressive 
MS. Their median disease duration was 10 years (range 2 to 22). The other 10 patients (5 females 
and 5 males, median age 58 years (range 43 to 76)) were known to have microangiopathic white 
matter lesions related to small-vessel ischaemic disease (in 7 cases) or migraine (in 3 cases). 
 
For the validation cohort, 20 patients were recruited: 13 of them had MS (comprising 6 females and 
7 males, median age 42 years (range 25 to 62)). Their median EDSS was 4.0 (range 0 to 6.0); 11 of 
them had relapsing-remitting MS, 2 had secondary progressive MS, and none had primary 
progressive MS. Their median disease duration was 10 years (range 2 to 21). The other 7 patients (5 
females and 2 males, median age 53 years (range 46 to 61)), were known to have microangiopathic 
white matter lesions related to hypertension associated small-vessel ischaemic disease (in 4 cases) 
or migraine (in 3 cases). 
 
3.3.2 Test results 
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Lesion characteristics on 3T scans for the test cohort are summarised in table 3.1, and example 
lesions are shown in figure 3.3. The MS group had a significantly higher proportion of lesions with 
perivenous appearance compared to the non-MS group (p<0.0001). All MS patients had central 
veins visible in >45% of brain lesions (median 72%, range 56% to 100%). All non-MS patients had 
central veins visible in <45% of lesions (median 8%, range 0% to 37%; figure 3.4). “Dawson’s 
finger”, “coffee bean”, and “donut” morphologically characteristic lesions were significantly more 
frequent in the MS group than in the non-MS group (p<0.0001). Total lesion numbers, perivenous 
lesion percentages, number of morphologically characteristic lesions, and patients’ diagnoses are 
shown in table 3.2. 
 
3.3.3 Estimates 
 
For the test cohort, agreement of 3T index test (i.e. whether proportion of perivenous lesions was 
above or below 45%) with the reference standard was 100% (lower bound of the one-sided 95% 
confidence interval is 86%). 
 
Inter-rater agreement on 3T lesion vein classification was very good (Cohen kappa coefficient = 
0.886, SE of kappa = 0.110), suggesting excellent reproducibility and that un-blinding based on 
perceived anatomical pattern of lesions had not influenced the primary observer’s classification. 
 
3.3.4 Validation of diagnostic rules 
 
By applying rules based on morphologically characteristic lesion counts the blinded observer (Dr 
Mistry) correctly categorised 20 out of the 20 subsequent scans. This took less than two minutes per 
scan.  
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3.4 Discussion 
 
T2*-weighted MRI enabled simultaneous visualisation of hyperintense MS lesions and their central 
veins, which appeared contrastingly hypointense due to the paramagnetic properties of 
deoxyhaemoglobin. Employing optimised T2*-weighted MRI in a standard 3T clinical scanner 
suggests that perivenous demyelination, as a pathologic hallmark of MS, could be relied upon as the 
primary MRI diagnostic feature. If confirmed in a large prospective cohort (including people 
presenting with CIS, with fewer lesions) using clinical scanners in multiple centres, the diagnosis of 
brain MRI lesions in cases of clinical uncertainty could be simplified. 
 
Diagnosis of MS currently relies on demonstrating dissemination of CNS lesions in space and time 
using a combination of clinical and investigative methods (Polman et al., 2011). At present, there is 
no single test that is diagnostic for multiple sclerosis, including MRI (Rudick and Miller, 2012). 
Brain white matter lesions are readily detected with MRI; however, most MRI techniques lack 
histopathological specificity. As a result, other conditions can produce MRI appearances which 
mimic those of MS (Rolak and Fleming, 2007). The lesions that most often cause diagnostic 
difficulty are incidental small-vessel ischaemic changes related to ageing, cerebrovascular disease 
or migraine (Pretorius and Quaghebeur, 2003). Fortunately, the clinical history and the anatomical 
pattern of MRI signal abnormalities usually allow differentiation of MS from other conditions 
(Fazekas et al., 1999). 
 
Among people referred to MS treatment centres with a possible diagnosis of MS, fewer than 50% 
are found to have MS, indicating that diagnosing MS in a significant minority of cases can be 
challenging (Carmosino MJ et al., 2005; Kelly et al., 2012).  Often patients with other neurological 
presentations not conforming to a typical clinically isolated syndrome (CIS) (e.g. headache), 
undergo brain MRI that raises radiological suspicions of demyelinating disease. Late-onset 
neurological symptoms associated with white matter brain lesions can also be diagnostically 
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challenging as those patients tend to have more coexistent vascular risk factors. The International 
Panel on the Diagnosis of MS make it clear that their criteria should be applied only when people 
have experienced a typical CIS or features of primary progressive MS (PPMS), thereby reinforcing 
specificity by ensuring a high “pre-test” probability of MS. In cases without typical CIS, or with 
contradictory conventional MRI findings, diagnostic dilemma and delay can impact on patients’ 
emotional wellbeing, as well as diverting further resources into additional tests and clinical 
assessments. The presence of cerebrospinal fluid oligoclonal bands (OCBs) at the time of initial 
presentation cannot always be relied upon; study results vary widely, but only 46% to 75% of newly 
presenting patients have OCBs (Tintoré et al., 2008), and OCBs can be present in conditions other 
than MS (Rolak and Fleming, 2007).  Increased MRI specificity for demyelinating lesions could 
strengthen future diagnostic criteria. 
 
Furthermore, some neurologists consider that treatment early in the course of MS following a CIS, 
or even after the diagnosis of radiological isolated syndrome, is possibly beneficial (Jacobs et al., 
2000; Comi et al., 2001; Kappos et al., 2007; Okuda and Vrenken, 2013). 
 
In the previous chapter a “cut-off” of 40% was used for the 7T MRI data, because that had been 
established by prior work using the same 7T MRI sequence in patients with known MS or non-MS 
brain lesions (Tallantyre et al., 2011). In the present 3T MRI study, a slightly different threshold of 
45% appeared more appropriate based on the results shown in figure 3.4. The fact that there is a 
difference is perhaps unsurprising, considering the differences between the 7T and 3T studies, 
including the strength of the susceptibility effect and image slice thickness. These factors influence 
the rate of true positive/negative and false positive/negative classification of perivenous lesions, 
which in turn will have an effect on the ideal threshold. 
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In the test cohort every single visible lesion was classified by Dr Mistry according to its perivenous 
status.  Certainly there are small lesions that have not been identified using our protocol, as there is 
no sequence at 3T that can identify all white matter demyelinating lesions.  Furthermore, in clinical 
practice, classifying every visible lesion in individuals with high lesion loads would be impractical. 
There are at least two potential ways to address this problem. One is a statistical approach: as 
advised by Dr Tench, Dr Mistry applied binomial distribution theory to calculate the accuracy with 
which diagnosis could be predicted if perivenous classification was applied to only 10 randomly 
selected lesions (in scans with more than 10 lesions). If 10 lesions are randomly selected from a 
patient's 3T T2*-weighted scan, 98.2% of MS patients and 1.2% of non-MS patients would have 4 
or more vein-positive lesions. Using binomial distribution theory and only analysing a sample of 10 
randomly selected lesions (in patients with >10 lesions) had accuracy comparable to analysing all 
the lesions, however, this is reliant on a sample of lesions being selected without bias. This may be 
difficult to achieve in clinical practice, as the first lesions noted are likely to be the largest or most 
obvious ones, rather than a random selection from the total population of lesions. Unbiased random 
selection of lesions may also be difficult to achieve if experienced clinicians and radiologists 
already favour a particular diagnosis based on clinical workup and conventional MRI findings. An 
alternative that overcomes these problems is a pattern-recognition based approach closer to 
neuroradiologists’ usual modus operandi. This leaves the onus with reporting neuroradiologists to 
appreciate the frequency of morphologically characteristic lesion appearances such as “coffee 
beans”, “donuts”, and “Dawson’s fingers” to enrich the specificity of data available to them, 
especially when conventional MRI appearances are equivocal or atypical. Incorporating this 
approach into a diagnostic “rule of six” proved to be sensitive, specific and time efficient when 
applied in our validation cohort.  
 
MS patients with few lesions in total have few morphologically characteristic lesions (for example, 
the MS patient with 4 morphologically characteristic lesions only had 6 visible lesions in total, and 
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they were all perivenous; table 3.2). The chance co-localisation of a non-MS lesion and a vein could 
mimic the appearance of a morphologically characteristic lesion, but the vast majority of 
accompanying non-MS lesions will not (for example, the non-MS patient with 5 morphologically 
characteristic lesions had 68 lesions in total, of which only 13% were perivenous; table 3.2). 
 
Susceptibility weighted images and also FLAIR* images (the product of T2*-weighted and FLAIR 
images), can be used to demonstrate the perivenous distribution of MS lesions with 3T and 7T MRI 
(Lummel et al., 2011; Sati et al., 2012; Kilsdonk et al., 2014). Further study is required to test the 
utility of FLAIR* in distinguishing between people with MS and those with microangiopathic brain 
lesions. Whilst FLAIR is more sensitive than T2*-weighted MRI for lesion detection, the purpose 
of our work is to augment the specificity of MRI for demyelinating lesions: future work could also 
compare the performance of FLAIR* and the T2*-weighted sequence we used for distinguishing 
the two pathologies. Although, for this study we have used anisotropic voxels, since the publication 
by Sati et al. we are employing their optimised  3D T2*-weighted sequence, that offers even easier 
identification of perivenous lesions in MS with very fast coverage of the whole brain volume, 
including  the posterior fossa (Sati et al., 2014). We anticipate that the search for the optimal 
sequence as well as image analysis or clinical reporting methodology will continue.  
 
In order to avoid false-positives, hyperintensities were not considered "lesions" unless they 
exceeded 4 voxels in their shortest dimension, so genuine lesions thinner than this were excluded 
from our analysis. Additionally, assessment of whether such small MS lesions have a central vessel 
was not attempted because of the limits of resolution (when using voxels with dimensions of 
0.55mm
2
 in-plane). 
 
There are many causes of white matter lesions in non-MS patients. In the most common of those 
diseases we would not expect to be able to detect perivenous demyelination and hence we believe 
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there is a value of the central vein sign. Our non-MS group included patients with many risk factors 
and certainly does not include sufficient numbers of all potential white matter diseases to be able to 
draw firm conclusions about the identification of central veins in other pathologies apart from MS. 
Although the clinical heterogeneity of the non-MS group should be noted with caution, it is 
reassuring though that in our study, the MS and non-MS patients were clearly separated in terms of 
the presence of central veins, suggesting that in clinical practice the detection of central vein at 3T 
could be useful. Future studies will no doubt study the presence of the central vein sign  using 
clinical scanners in other more uniform groups of non-MS patients with white matter disease as 
already has been done for Susac’s syndrome and NMO using 7T MRI (Sinnecker et al., 2012; 
Wuerfel et al., 2012; Kister et al., 2013). In our MS cohort we did not fully quantify how many had 
all the possible vascular comorbidities for white matter lesions, such as high blood pressure, 
tobacco use, and migraine. This would be an important factor to include in future studies, since a 
large group of MS patients with such comorbidities could influence how well our proposed 
technique performs (i.e. it could lead to a “false-negative” diagnosis if an MS patient has fewer than 
6 demyelinating lesions with a visible central vein, that are outnumbered by comorbid non-
perivenous lesions).  
 
To conclude, our findings suggest optimised 3T T2*-weighted MRI can be used to differentiate 
between individuals with MS and those with microangiopathic brain lesions. If validated in a large 
prospective cohort, this technique could complement existing diagnostic algorithms by improving 
the specificity with which MRI demonstrates inflammatory demyelinating brain lesions. It could 
also expedite diagnosis and avoid the further (often invasive) paraclinical tests and protracted 
uncertainty experienced by many people suspected to have MS. 
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Figures and tables 
 
Figure 3.1 3T T2* MRI characteristic lesion morphologies in people with MS 
3T T2*-weighted MRI. The top row shows periventricular lesions with a “Dawson’s finger” 
appearance. White matter lesions are shown with a “coffee bean” appearance in the middle row and 
a “donut” appearance in the bottom row. 
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Figure 3.2 Examples of perivenous lesion morphology according to vein orientation  
3T T2*-weighted MRI. The left image shows a “coffee bean” lesion where a central vein remains 
within the plane of the image slice for the entirety of its course through the lesion, bisecting the 
lesion. The right image shows a “donut” lesion, where the central vein is perpendicular to the plane 
of the image slice, showing the central venous hypointensity as a circular dot. The middle image 
shows a perivenous lesion in which the central vein passes diagonally through the plane of the 
image slice; this still gives a “coffee bean” appearance, because the central dot becomes elongated, 
but the vein does not bisect the lesion edge-to-edge. 
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Figure 3.3 Examples of lesions detected using optimised 3T T2*-weighted MRI 
3T T2*-weighted MRI. These T2*-weighted images (with insets showing white matter lesions) 
were acquired using a standard 3T MRI system. The top row shows examples of lesions from 
people with MS. The top left image’s inset shows an MS lesion apparently formed by the 
coalescence of three neighbouring lesions, each with its own central vein, resulting in a lesion with 
multiple central veins. The other MS lesions shown have a single central vein, appearing as a line or 
a dot of hypointensity through their centre. Contrastingly the lesion examples from non-MS patients 
shown in the middle row do not appear to contain veins. The bottom row shows examples of “false 
positive” lesions from non-MS patients that do appear to contain a vein. 
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Figure 3.4 Distribution of 3T MRI results according to patients’ diagnoses in the test 
cohort 
Perivenous lesion percentages for 10 people known to have MS and 10 people known to have 
microangiopathic brain white matter lesions (test cohort) are shown in this plot. Each patient could 
be categorised into the correct disease group according to whether the percentage of perivenous 
lesions was above or below 45%. 
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Table 3.1 Summary of lesion characteristics in the test cohort, including percentage of 
lesions in each anatomical category 
 
 
3T cross-sectional study  MS group  Non-MS group  
No. of subjects  10  10  
Total lesion count  436  489  
Median lesions per subject (range)  35 (6 – 142)  50 (7 – 107)  
Median lesion volume (range) (mm3)  51.1 (4.4 – 14339.5)  22.6 (1.6 – 7459.9)  
PV %  24.1  3.3  
DW %  48.4  79.1  
JC %  27.5  17.6  
 
PV = periventricular; DW = deep white matter; JC = juxtacortical  
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Table 3.2 Cross-tabulation of 3T test MRI findings and patients’ diagnoses 
The non-MS patient category included those who had microangiopathic brain white matter lesions 
due either to migraine or small vessel ischaemic disease. MCLs = morphologically characteristic 
lesions. * People with a clinical diagnosis of migraine. 
 
Total lesions  Perivenous %  Total MCLs  Actual diagnosis  
142 56 32 MS  
57 61 12 MS  
41 66 13 MS  
12 67 5 MS  
30 70 11 MS  
71 73 37 MS  
8 75 6 MS  
45 84 18 MS  
24 88 12 MS  
6 100 4 MS  
46 4 1 Small vessel ischaemia* 
64 6 1 Small vessel ischaemia* 
22 9 0 Small vessel ischaemia* 
11 0 0 Small vessel ischaemia  
107 4 0 Small vessel ischaemia  
79 8 3 Small vessel ischaemia  
68 13 5 Small vessel ischaemia  
55 16 2 Small vessel ischaemia  
7 29 1 Small vessel ischaemia  
30 37 2 Small vessel ischaemia  
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Chapter 4: Focal Multiple Sclerosis Lesions Abound In “Normal Appearing 
White Matter” 
 
4.1 Introduction 
Quantitative MR techniques have enabled in vivo demonstration of alterations in MS “normal 
appearing white matter” (NAWM). The aetiology and pathological substrate of processes affecting 
NAWM remain unclear but three main explanations exist (figure 4.1) (Filippi, Tortorella, et al., 
1999).  
 
Macroscopic white matter lesions are known to exert effects on functionally connected NAWM via 
Wallerian degeneration (Evangelou et al., 2000), and trans-synaptically (Evangelou et al., 2001). 
However, this fails to explain fully why marked NAWM abnormalities are also observed in primary 
progressive MS (Davie et al., 1997; Filippi, Iannucci, et al., 1999), in which imaging typically 
reveals relatively few visible white matter lesions. Cytokines have been implicated in mediating MS 
symptoms without intermediary acute inflammatory plaque formation (Moreau et al., 1996), and 
up-regulation of both pro-inflammatory and anti-inflammatory genes has been shown in NAWM in 
MS (Zeis et al., 2008). T2-weighted MRI sequences such as fluid attenuation inversion recovery 
(FLAIR) are accepted as having excellent sensitivity to MS white matter lesions (Moraal et al., 
2008); they are therefore commonly used to segment-out areas of visible white matter abnormality 
and thus to define NAWM. Use of high field and ultra-high field MRI has already uncovered small 
MS lesions undetected using 1.5T MRI (Keiper et al., 1998; Kollia et al., 2009). In clinical settings 
3T MRI employing a highly sensitive sequence such as FLAIR is regarded as the investigation of 
choice to detect demyelinating lesions. No prior studies have examined whether small discrete 
white matter lesions exist within areas classified as normal using 3T FLAIR MRI. This might have 
diagnostic implications in a few individuals and would also contribute to a better understanding of 
NAWM pathology. 
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In previous studies comparing MRI lesion detection sensitivity against histopathology, white matter 
lesions were missed with imaging. However those studies were performed using low field strength 
MRI scanners (Newcombe et al., 1991). Subsequent use of 4.0T MRI systems detected many brain 
MS lesions in vivo that were missed using 1.5T MRI (Keiper et al., 1998); consequently high-field 
T2-weighted MRI has generally been regarded as having exquisite sensitivity for MS WML. In the 
spinal cord 4.7T MRI seems able to demonstrate virtually all MS lesions detectable 
histopathologically (Nijeholt et al., 2001; Gilmore et al., 2009). However, it is not clear whether 
there are still histopathologically detectable brain WML that are missed using modern high-field or 
ultra-high-field MRI. Much recent historadiological correlation work has instead focused on MRI’s 
sensitivity for cortical lesions, but from those data it may still be possible to comment on MRI’s 
sensitivity to WML by considering detection rates of leucocortical (i.e. mixed, or “type 1”) lesions. 
While MRI sensitivity for purely intracortical lesions remains disappointingly low regardless of 
field-strength or sequence used (Kilsdonk et al., 2016), nearly all leucocortical lesions are reliably 
detected c.f. histopathology when using 1.5T and 4.7T MRI (Geurts et al., 2008). Using 7T MRI 
apparently all histopathologically defined lesions are detected (Kilsdonk et al., 2016). However, as 
formalin fixation reduces T1 and T2 relaxation times, any correlations between fixed tissue and in 
vivo data are complicated (Schmierer et al., 2008). Additionally (unlike in vivo MRI), scanning of 
post mortem tissue is not constrained by the limitations of SAR, scan duration and patient 
movement.  
 
Post mortem histopathological confirmation of additional lesions (c.f. FLAIR) found using in vivo 
MRI sequences was beyond the scope of this study. Instead we sought histopathological equivalents 
of our in vivo MRI findings, using pre-existing post mortem tissue obtained from other people with 
MS. 
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Currently 7T MRI remains a research tool and is not used in clinical practice. The increase in field 
strength leads to an increase in SNR, allowing a combination of improvement in spatial resolution 
and shorter acquisition times. Ultra-high field imaging in MS has shown promise in the detailed 
characterisation of cortical lesions (Kangarlu et al., 2007; Kollia et al., 2009; Mainero et al., 2009; 
Schmierer et al., 2010), and also white matter lesions in MS (Tallantyre et al., 2008). However 
there are also technical challenges, and optimisation of inversion recovery spin echo sequences such 
as FLAIR remains challenging at 7T, principally due to inhomogeneities in the RF pulse flip angle 
across the head. While RF inhomogeneities also affect other pulse sequences, in our experience 3D 
magnetisation prepared rapid acquisition gradient echo (MPRAGE) at 7T does not reflect this 
inhomogeneity as dramatically, has the advantage of providing good contrast between lesions and 
the adjacent white matter, and offers rapid acquisition times with good anatomical coverage and 
high resolution isotropic voxels. Hence we elected to compare standard clinical 3T FLAIR and 
MPRAGE sequences with the 7T MPRAGE. 
 
The objective of this study was to investigate whether high field and ultra-high field T1-weighted 
MPRAGE MRI enables detection of MS white matter lesions in areas defined as NAWM using 
high field T2-weighted FLAIR MRI; i.e. to ascertain whether undetected lesions are likely 
contributors to the burden of abnormality in similarly defined NAWM. 
 
4.2 Patients and methods 
4.2.1 Participants 
 
Patients known to have clinically definite MS were recruited from the Neurology outpatients 
department at Nottingham University Hospitals NHS Trust, UK by Dr Evangelou. Patients who had 
received corticosteroid treatment within six months prior to this study were excluded. On the day of 
the MRI scan, disability was assessed in clinic by the patient’s treating physician using EDSS 
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(Kurtzke, 1983). Healthy volunteers were recruited by local advertisement. Each participant 
provided prior written informed consent. This study was approved by Nottingham Local Research 
Ethics Committee. 
 
4.2.2 Image acquisition 
 
For each patient 3T and 7T scans were obtained on the same day. The healthy volunteers had 7T 
scans only. 7T images were acquired using a Philips Achieva system (Philips Medical Systems, 
Best, The Netherlands) equipped with whole-body gradients, a 16-channel head-only parallel 
imaging SENSE receive coil and a head-only volume transmit coil (Nova Medical, Inc., 
Wilmington MA). Dr Dixon operated the scanner console, with Dr Mistry or Dr Tallantyre present 
in all cases. Images were acquired using a 3D T1-weighted MPRAGE sequence (192 x 164 x 100 
mm
3
 field of view; 0.5-mm isotropic voxels; TE = 6.5 ms; TR = 14 ms; TI = 1033 ms; inter-shot 
interval = 3000 ms; flip angle = 8
o
; acquisition time 11.9 minutes) and a 3D gradient-echo sequence 
with strong T2*-weighting (200 transverse slices in 4 overlapping stacks, interleaved to decrease 
imaging time, giving a field of view of 192 x 164 x 85 mm
3
; 0.5-mm isotropic voxels; TE = 20 ms; 
TR = 150 ms; flip angle = 14
o
; parallel imaging factor 2 (RL direction); EPI factor 3; acquisition 
time 8.8 minutes). 
 
3T images were acquired using a Philips Achieva system (Philips Medical Systems, Best, The 
Netherlands) equipped with whole-body gradients, an 8-channel head-only parallel imaging SENSE 
receive coil and a whole-body transmit coil. Dr Dixon operated the scanner console, with Dr Mistry 
or Dr Tallantyre present in all cases. Images were acquired using a 3D T1-weighted MPRAGE 
sequence (164 x 164 x 118 mm
3
 field of view; 0.8-mm isotropic voxels; TE = 2.3 ms; TR = 7.6 ms; 
TI = 960 ms; inter-shot interval = 3000 ms; flip angle = 8
o
; acquisition time 9.4 minutes) and a 2D 
multi-slice FLAIR sequence (256 x 204 x 140 mm
3
 field of view, 1 x 1 x 2.5 mm
3
 voxels; echo 
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train length 27; 120
o
 refocusing pulse; TE = 125 ms; TR = 11 s; TI = 2800 ms; acquisition time 6 
minutes). No interpolation was performed at acquisition for any of the sequences. 
 
4.2.3 Data analysis 
 
Dr Tallantyre identified all visible white matter lesions on 3T FLAIR images. Dr Mistry (blinded to 
FLAIR data) independently identified all visible white matter lesions on 3T MPRAGE and 7T 
MPRAGE images. Comparisons were then performed by Dr Mistry to ascertain if each individual 
lesion was identified prospectively on 3T FLAIR, 3T MPRAGE, or 7T MPRAGE. Ascertaining 
whether each individual lesion was detected on each sequence is more representative of lesion 
detection. Drawing conclusions based on simple lesion counts is fraught with difficulties since 
lesion appearances differ between sequences (which can impact on the lesion counts) as illustrated 
in figure 4.2. Additional (i.e. not seen on FLAIR) abnormalities found on 3T and 7T MPRAGE 
were reviewed by an experienced Neuroradiologist (Dr Jaspan); thus consensus was reached with 
the Neuroradiologist that additional abnormalities identified using high field MPRAGE were 
consistent with MS lesions. These additional abnormalities seen on MPRAGE were also cross-
checked against 7T T2*-weighted images (and against 3T FLAIR) by Dr Mistry; this allowed 
exclusion of MPRAGE “false positives” caused by misinterpretation of hypointensities due to blood 
vessels or Virchow-Robin (or other CSF) spaces. 
 
Dr Mougin registered all of the acquired images to the same space using FLIRT in FSL 
(www.fmrib.ox.ac.uk/fsl/ ) (Jenkinson et al., 2002). Dr Mistry drew “regions of interest” around 
visible abnormalities (using a semi-automatic intensity threshold seeding technique), and then 
calculated lesion map overlaps using an in-house software package 
(https://www.nottingham.ac.uk/research/groups/clinicalneurology/neuroi.aspx). Analysis was 
restricted to supratentorial volumes because the existing 7T receive coil yielded poor SNR 
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infratentorially. All lesions without overlapping counterparts in the other sequences were visually 
checked by Dr Mistry to eliminate potential errors in the event of imperfect co-registration of the 
images. The volume of each lesion detected on MPRAGE images was calculated by Dr Mistry 
using the lesion maps. 
 
If a lesion was not identified on one or two of the three (3T FLAIR, 3T MPRAGE, 7T MPRAGE) 
sequences, its anatomical location was categorised by Dr Mistry. The location categories were: 
periventricular (lesion edge touching or within 2mm of ventricular border), subcortical (lesion edge 
within 2mm of cortex, but not touching cortex) or juxtacortical (white matter lesion which touches 
cortex), deep white matter (white matter lesions not encroaching within 2mm of cortex or ventricle), 
and deep grey matter. 
 
4.2.4 Statistical methods 
 
Dr Tench devised the statistical methodology which was applied by Dr Mistry. The “GenStat” 
software package (http://www.vsni.co.uk/software/genstat/) was used for statistical analysis. A 
paired sample t-test was applied to the null hypothesis that the difference between the numbers of 
additional lesions found for each patient on 7T MPRAGE compared to the numbers of additional 
lesions found on 3T MPRAGE is equal to 0.  To test whether the volume of the lesions seen on both 
FLAIR and MPRAGE is different from the volume of lesions seen only on MPRAGE, we applied a 
two sample t-test with the null hypothesis that there is no significant difference between the 
volumes of lesions that were also seen on 3T FLAIR vs. those that were not. 
4.3 Results 
4.3.1 Participants 
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Fourteen patients were recruited for the study. All of them had clinically definite MS. Their mean 
age was 41 years (range 24 – 60), mean disease duration was 12.0 years (range 1.2 – 25.0), and 
median EDSS was 2.5 (range 0 – 6.5). Disease course was as follows: 11 had relapsing–remitting 
MS, 2 had secondary progressive MS and 1 had primary progressive MS. Nine of them were 
receiving disease modification treatment (1 on azathioprine, 5 on beta interferon and 3 on 
glatiramer acetate). None had received corticosteroid treatment within six months prior to this 
study. Three healthy volunteers (one man aged 45, and two women of age 29 and 30) were also 
recruited. 
 
4.3.1 Test results 
 
Total lesion counts according to the sequence used were: 7T MPRAGE, 1075 lesions; 3T 
MPRAGE, 967 lesions; 3T FLAIR, 812 lesions. However, these totals misrepresent lesion detection 
using FLAIR imaging for the reasons discussed in data analysis methods above, and as depicted in 
figure 4.2.  Examples of lesions found on MPRAGE and not on FLAIR are shown in figure 4.3. 
 
Although the majority of lesions were detected both on FLAIR and MPRAGE images, a substantial 
proportion were only detected using 3T MPRAGE (186 lesions, i.e. 19% of the total number of 
lesions detected) and 7T MPRAGE (231 lesions*, i.e. 22% of the total number of lesions detected). 
Of those additional (i.e. not found on 3T FLAIR) lesions detected using 3T and 7T MPRAGE, over 
half were juxtacortical or subcortical (see figure 4.4). Significantly more additional lesions were 
detected using 7T MPRAGE compared to 3T MPRAGE (p=0.012) as shown in figure 4.5. Direct 
comparison of lesion detection using 3T MPRAGE vs. 7T MPRAGE is shown in figure 4.6. In the 
lower half of the brain the SNR of the 7T images started to become suboptimal; this at least partly 
explains why some lesions were missed on 7T MPRAGE cf. 3T FLAIR/MPRAGE (see discussion). 
*(of which 94 were also detected using 3T MPRAGE) 
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In two of the three healthy volunteers no lesions were seen on 7T MPRAGE images. The 29 year 
old female healthy volunteer had three small discrete white matter lesions, not accounted for by 
veins, Virchow-Robin spaces or other CSF spaces when checked against T2*-weighted and FLAIR 
imaging. 
 
Considering lesion volumes calculated from 3T MPRAGE and 7T MPRAGE lesion maps, those 
lesions not found using FLAIR were significantly smaller than those that were (p < 0.001). Volume 
data is summarised in table 4.1. 
 
 
4.4 Discussion 
 
There is a growing body of evidence that the radiologically observed changes in NAWM are 
clinically relevant in MS (Ruiz-Peña et al., 2004; Sastre-Garriga et al., 2005; Khaleeli et al., 2007). 
Studies using MR techniques including magnetisation transfer, T1 relaxation time mapping, 
spectroscopy and diffusion tensor imaging continue to uncover abnormalities in NAWM in people 
with MS (Filippi, Tortorella, et al., 1999; Griffin et al., 2002; Castriota-Scanderbeg et al., 2004; De 
Stefano and Filippi, 2007; Filippi and Agosta, 2007; Rovaris and Filippi, 2007; Neema et al., 2009; 
Sajja et al., 2009). 
 
In this study, we used 3T and 7T MPRAGE MRI to identify lesions in areas of white matter that 
were defined as NAWM using 3T FLAIR. It follows that discrete lesions such as these are likely to 
contribute to the radiological changes that have been reported in NAWM. The total volume of the 
additional lesions found using MPRAGE was relatively small, but their contribution to NAWM 
abnormality should not be assumed to be proportionately small. There are two reasons for this: 
firstly, it is known that pathological effects of focal MS lesions project beyond the lesion and into 
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surrounding NAWM (Evangelou et al., 2000, 2001); secondly, it is probable that there are yet more 
focal lesions (perhaps even smaller) which were undetected in our study. 
 
FLAIR MRI is used routinely in clinical practice (alongside other T2-weighted spin echo 
sequences) to detect MS lesions on account of its high sensitivity (Moraal et al., 2008), aided by its 
combination of strong T2-weighting and CSF signal suppression. Currently, acquiring high quality 
FLAIR images at 7T is challenging, preventing us from performing a direct comparison of 7T 
FLAIR vs. 3T FLAIR during the period over which this study was performed. Three-dimensional 
MPRAGE was more practical to implement at both field strengths whilst also maintaining good 
contrast between lesions and adjacent white matter, relatively short acquisition times, and 
(especially at ultra-high field) high spatial resolution. 
 
The focus of this study was not to examine “which sequence is best for overall lesion detection”; 
indeed many lesions were detected using 3T FLAIR which were not identified on MPRAGE 
images. Table 4.2 shows counts of lesions (per patient) detected on 3T FLAIR that were missed on 
7T MPRAGE, according to whether they were located in the bottom or top half of the supratentorial 
volume. A paired t-test was applied to the differences in numbers of lesions detected in the bottom 
(group one) vs. top (group two) halves of the supratentorial volume. Significantly more lesions were 
missed on 7T MPRAGE in the bottom half of the supratentorial volume compared to the top half 
(p=0.0172). The mean of Group One minus Group Two equals 3.00, and the 95% confidence 
interval of this difference was 0.62 to 5.38.  
 
Instead we have focused on trying to determine whether additional small demyelinating lesions 
exist which could account for some of the NAWM abnormality. In our study, image slice thickness 
was greatest for 3T FLAIR, intermediate for 3T MPRAGE and smallest for 7T MPRAGE. It is 
known that reduction in slice thickness enables visualisation of greater numbers of smaller lesions 
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(Molyneux et al., 1998). However, it is unlikely that slice thickness alone accounts for all the 
additional lesions detected using MPRAGE images. As can be seen in table 4.1, there was some 
variance in the size of additional lesions detected using both 3T and 7T MPRAGE (i.e. though 
smaller on average, lesions undetected on FLAIR were not uniformly small). We postulate a 
combination of slice thickness/resolution, increased SNR (at least near the cranial vertex, using the 
existing 7T receive coil) afforded by ultra-high field strength, and differing contrast mechanisms of 
MPRAGE vs. FLAIR offered complementary information contributing to the detection of additional 
lesions on MPRAGE images. 
 
A disadvantage of MPRAGE is that MS lesions, veins and CSF are all hypointense: necessitating 
the additional steps of cross-checking MPRAGE findings with T2*-weighted and FLAIR images. 
On MPRAGE images veins in cross-section can be similar in appearance to small lesions, both 
appearing as small circular hypointensities, if viewed on a single slice in isolation. Veins can 
usually be distinguished from small spherical or ovoid lesions, because veins are comparatively 
longitudinally extensive through adjacent slices. Another limitation of this study is that the MRI 
sample size was small. Larger studies would be required to characterise differences in lesion counts 
between different MS clinical course types and levels of disability, e.g. to measure correlation 
between subcortical lesion load and cognitive impairment. 
 
A strength of this study was that we avoided drawing conclusions based on simple lesion counts. 
Though time-consuming, ascertaining whether each individual lesion was detected on each 
sequence is more representative of lesion detection performance. 
In our study, more than half the additional lesions detected using 3T and 7T MPRAGE were 
subcortical or juxtacortical. This is despite the fact that detection of subcortical lesions has been 
regarded as a specific strength of FLAIR imaging (Boggild et al., 1996; Kates et al., 1996; 
Bastianello et al., 1997; Filippi et al., 1998). MS subcortical white matter lesions are more likely to 
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cause significant cognitive impairment than comparable lesion loads in other locations (Damian et 
al., 1994). A 1.5T MRI study found fast-FLAIR to be superior to conventional spin echo in 
identifying juxtacortical MS lesions, and presence of these lesions correlated with impaired 
performance in verbal memory tasks (Moriarty et al., 1999). Lesion load in U-fibres has been 
associated with impaired memory and executive function, using conventional T2-weighted MRI 
(Miki et al., 1998).  
 
In conclusion, we have demonstrated that MRI with 3T and 7T MPRAGE enables detection of MS 
lesions in areas defined as NAWM using standard clinical 3T FLAIR. Focal MS lesions contribute 
to the abnormalities known to exist in what has previously been classified as the NAWM. In future, 
inclusion of 7T MPRAGE-visible lesion maps may refine segmentation of NAWM. Improved 
segmentation of NAWM should augment accuracy of analyses involving NAWM metrics. Thus, 
future studies using (e.g. diffusion or MT) maps of NAWM could be better placed to improve our 
knowledge about the other possible mechanisms leading to damage beyond discrete lesions.  
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Figures and tables 
Figure 4.1 Proposed explanations for the abnormalities known to exist in NAWM 
Whilst there is evidence supporting hypotheses that diffuse factors and damage to axons traversing 
lesions contribute to the abnormalities in NAWM, until now evidence has been lacking that NAWM 
contains substantial numbers of small focal lesions undetected using high field imaging (i.e. 3T 
FLAIR). 
 
NAWM
abnormality
Discrete lesions beyond 
the resolution of 
conventional scanning
Diffuse factors 
dependent or 
independent of 
macroscopic pathology
Damage to axons 
traversing focal lesions
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Figure 4.2 Differences in lesion counting when using MPRAGE and FLAIR images 
Left image: 3T FLAIR MRI; right image: 7T MPRAGE MRI. On FLAIR images neighbouring 
lesions appeared as confluent hyperintense regions. On MPRAGE images the corresponding lesions 
appeared as more numerous discrete hypointensities. 
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Figure 4.3 Examples of lesions prospectively identified on MPRAGE images and not 
on 3T FLAIR 
Left column: 3T FLAIR MRI; middle column: 3T MPRAGE MRI; right column 7T MPRAGE 
MRI. Examples of typical lesions detected by the observer using MPRAGE but not by the observer 
using 3T FLAIR images. The example in the third row was detected using 3T MPRAGE and 7T 
MPRAGE.  The other examples were only detected using 7T MPRAGE. 
 
3T FLAIR 3T MPRAGE 7T MPRAGE
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Figure 4.4 Anatomical distribution of additional lesions detected using MPRAGE 
Pie chart labels: JC = Juxtacortical, SC = Subcortical, DW = Deep white matter, PV = 
Periventricular, DG = Deep grey matter 
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Figure 4.5 Significantly more extra lesions were found using 7T MPRAGE than using 
3T MPRAGE 
Number of additional (i.e. not detected using FLAIR) lesions detected using 7T and 3T MPRAGE 
for each patient.  
PP = primary progressive, RR = relapsing remitting, SP = secondary progressive 
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Figure 4.6 Comparison of lesion detection using 3T MPRAGE vs. 7T MPRAGE 
The majority of lesions were common to both 3T and 7T MPRAGE. More lesions were seen on 7T 
MPRAGE only than on 3T MPRAGE only. 
 
3T MPRAGE vs. 7T MPRAGE
261164 814
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 Table 4.1 MPRAGE lesion volume comparison 
 
7T MPRAGE lesion volumes (mm
3
) 
 
3T MPRAGE lesion volumes (mm
3
) 
 
 
Lesion type Mean S.D. 
 
Lesion type Mean S.D. 
Not seen on FLAIR 11.2 15.2 Not seen on FLAIR 13.5 29.6 
Also seen on FLAIR 96.6 334.3 Also seen on FLAIR 103.5 518.0 
 
 
 
 
 
 
Table 4.2 Counts of lesions (per patient) detected on 3T FLAIR that were missed on 7T 
MPRAGE 
 
  
Patient 1 2 3 4 5 6 7 8 9 10 11 12 13 14 total 
7T missed FLAIR 
lesions bottom half of 
supratentorial volume 4 3 15 13 20 9 10 7 2 12 7 7 3 3 115 
7T missed FLAIR 
lesions top half of 
supratentorial volume 6 1 4 16 11 5 10 4 4 7 3 0 1 1 73 
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Chapter 5: A Corticocentric Model For MS Pathogenesis 
 
5.1 Introduction 
Demyelinating white matter lesions (WML) and clinical relapses are two of the most striking 
features of multiple sclerosis (MS); understandably they have been central to traditional 
pathogenetic and therapeutic precepts about MS. Despite their prominence, MS relapses are not 
directly related to long-term disability progression (Confavreux et al., 2000, 2003; Kremenchutzky 
et al., 2006). Accordingly, MRI-visible focal WML load in the brain or spinal cord fails to fully 
explain disability and progression in MS (Thompson et al., 1990; Kidd et al., 1993; Barkhof, 2002). 
 
Normal appearing white matter (NAWM) axon loss (rather than focal demyelination in WML) is 
the pathological substrate underlying chronic, irreversible disability in MS (Tallantyre, Bø, et al., 
2010). Changes in MR metrics reflecting interlinked demyelination and axon loss in the NAWM 
(and normal appearing grey matter) correlate well with disability in MS (De Stefano et al., 1998; 
Traboulsee et al., 2003; Ruiz-Peña et al., 2004; Sastre-Garriga et al., 2005). This involvement of the 
normal appearing brain tissues occurs early in the course of MS (De Stefano et al., 2002, 2003),  
and is only partly related to WML (Filippi and Rocca, 2005). 
 
The spastic paraparesis that typifies disabling MS is underpinned by axon loss in the corticospinal 
tract (Ganter et al., 1999; Bjartmar et al., 2000; Wilson et al., 2003). Post mortem cerebral WML 
burden does not correlate with axon loss in the corticospinal tracts on histopathology (DeLuca et 
al., 2006). Several studies have found that in vivo cerebral or spinal cord WML burden on MRI 
does not correlate with quantitative MR estimates of axon loss in the corticospinal tracts, or the 
whole NAWM (using magnetisation transfer ratio (MTR), and other measures) (Rovaris et al., 
2000; Griffin et al., 2002; Filippi et al., 2003; Wilson et al., 2003; Filippi and Rocca, 2007; 
Bellmann-Strobl et al., 2009). In another MTR study which used tissue diffusion characteristics to 
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segment white and grey matter of the brain, all MTR histogram derived metrics for NAWM and 
normal appearing grey matter were significantly lower in people with MS vs. healthy controls; 
furthermore moderate correlation was found between T2 WML volumes and the peak height of the 
normal appearing grey matter MTR histogram (Cercignani et al., 2001). However, caution must be 
applied in the interpretation of correlations with “normal appearing grey matter” as defined using 
any existing MRI technique, as it is likely riddled with occult focal lesions (Kilsdonk et al., 2016). 
 
Whilst it is evident that axon loss and disability are at least partly independent of WML, the true 
mechanism of disease has remained uncertain. Cortical lesions are functionally connected to remote 
NAWM just as WML are. Many studies have tested the relationship between macroscopic WML 
and diffuse NAWM disease. The same cannot be said for cortical lesions. Previous work has shown 
that 7T magnetisation-prepared-rapid-acquisition-gradient-echo (MPRAGE) MRI performs 
favourably for cortical lesion detection (Tallantyre, Morgan, et al., 2010). The objective of this 
study was to assess correlation between cortical lesion load on 7T MRI, and the MTR of the 
NAWM, in order to test the hypothesis that cortical lesions cause NAWM axon loss. 
 
5.2 Patients and methods 
5.2.1 Participants 
 
People with clinically definite MS were recruited from Neurology outpatients at Nottingham 
University Hospitals NHS Trust by Dr Evangelou, Dr Mistry and Dr Abdel-Fahim. All participants 
gave prior informed consent and the study had received ethical approval from the local research 
ethics committee. Disease duration data was obtained from hospital records, and disability was 
assessed in clinic by the patient’s treating physician using EDSS (Kurtzke, 1983). 
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5.2.2 Image acquisition 
 
All images were acquired using a Philips Achieva 7T MRI system, equipped with whole-body 
gradient coils, a head-only quadrature transmit RF coil, and a NOVA 32 channel SENSE receive 
coil. Dr Mougin operated the scanner console, with Dr Mistry or Dr Abdel-Fahim present in all 
cases. 
 
MPRAGE images were acquired using a tailored inversion pulse to reduce effects of B1 
inhomogeneity (Hurley et al., 2010). Acquisition parameters were: TI 1070ms, flip angle 8˚, TE 
7ms, TR 15ms, voxel size 0.5x0.5x0.5mm
3
, field of view 205×215×140mm
3
, acquisition time 10 
minutes 11s. 
 
Dr Mougin produced MTR maps from an acquisition giving two images (MTsat and MTno-sat). The 
sequence used a turbo-field echo (TFE) readout.  The MTsat was acquired by applying 20 off-
resonance pulses (sinc pulses with bandwidth of 300 Hz and off-resonance by 1.0 kHz (-3.4ppm), 
20ms between each pulse) before each TFE readout train. Acquisition parameters were: TR 12ms, 
TE 6.4ms, flip angle 8˚, voxel size 0.5×0.5×1mm3, field of view 205×175×80mm3, centre-out 
sampling, shot to shot interval 10s, acquisition time 8minutes 50s. High resolution MTR maps were 
calculated from (MTnoSat-MTSat)/MTnoSat on a pixel by pixel basis after registration of the two 
volumes of interest using FLIRT in FSL (http://www.fmrib.ox.ac.uk/fsl/). 
 
Owing to the less extensive MTR field of view, and reducing MPRAGE signal-to-noise-ratio 
infratentorially, brainstem and posterior fossa structures were not included in any of the analysis. 
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5.2.3 Data analysis 
5.2.3.1 Cortical lesion detection 
 
All image data had been anonymised. So that apparent WML lesion load would not bias the 
observer segmenting cortical lesions (Dr Abdel-Fahim), only cortical ribbons were presented; with 
the white matter, cerebellum, and deep grey matter removed by Dr Mougin. Dr Mougin generated 
cortical ribbons by segmenting MPRAGE volumes using the Freesurfer image analysis suite 
(http://surfer.nmr.mgh.harvard.edu/), and he additionally manually edited the ribbons to remove any 
WML erroneously included by the automated segmentation. 
 
Dr Abdel-Fahim manually drew cortical lesion maps on the cortical ribbons, on a slice-by-slice 
basis using the ImageJ analysis suite (http://rsb.info.nih.gov/ij/). Cortical lesion maps were used to 
calculate total cortical lesion volume as well as lesion counts for each subject. 
 
Whilst the objective of cortical lesion segmentation was to ascertain cortical lesion load, currently 
no imaging modality is able to reliably demonstrate 100% of cortical lesions present. We could not 
validate our in vivo cortical lesion counts against the gold standard of histopathology. In order to 
verify whether MPRAGE cortical lesion counts reliably reflect underlying cortical lesion load, we 
used comparator cortical lesion counts obtained using an entirely independent contrast mechanism. 
The signal-to-noise and spatial resolution of 7T MRI allowed us to use MTR as an imaging 
modality (in addition to using it for measuring average tissue properties). Cortical ribbons were 
generated from MTR images by Dr Mougin (which had been registered to the MPRAGE images by 
Dr Mougin using FSL (www.fmrib.ox.ac.uk/fsl/)), by masking them with the MPRAGE cortical 
ribbons previously segmented. The observer who segmented lesions in the MPRAGE cortical 
ribbons (Dr Abdel-Fahim) did the same using MTR cortical ribbons, which had been randomised 
and anonymised, so they could not be matched with the corresponding MPRAGE. Correlation 
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between cortical lesion counts using the independent contrast mechanisms of MPRAGE and MTR 
was calculated by Dr Mistry; a tight correlation would suggest that each mechanism yielded counts 
proportional to the real cortical lesion load. Because inter-observer reproducibility would not show 
whether MTR or MPRAGE lesion counts related to true underlying lesion load, it was considered 
beyond the scope of the current study and not performed. 
 
5.2.3.2 NAWM segmentation following WML detection 
 
A second observer (Dr Mistry) independently identified WML in anonymised 7T MPRAGE 
images. For WML detection, 7T MPRAGE has sensitivity exceeding that of 3T FLAIR MRI 
(Mistry et al., 2011). The previously generated cortical ribbons were subtracted from MPRAGE 
volumes prior to WML detection by Dr Mougin, so that apparent cortical abnormalities would not 
influence the observer looking for WML. Dr Mistry then drew WML maps semi-automatically on a 
lesion-by-lesion, slice-by-slice basis using an intensity-based flood-fill function in the NeuRoi 
image analysis program (http://www.nottingham.ac.uk/scs/divisions/ 
clinicalneurology/software/neuroi.aspx). Previous work comparing lesion appearances on 7T 
MPRAGE and 3T FLAIR showed that FLAIR lesion hyperintensity extended beyond the edge of 
the lesion as depicted using 7T MPRAGE (Mistry et al., 2011). WML maps were 3D-dilated by 5 
voxels using a tool in NeuRoi (i.e. approximately 2.5mm dilatation from lesion surface), to 
encompass these beyond-edge effects in proximity to WML. 
 
White matter volumes were produced by Dr Mistry in two steps using NeuRoi: 1) initial 
classification of white matter using automated template-based segmentation, 2) subtraction of 
previously generated cortical ribbons from white matter segments (to remove any cortical tissue 
erroneously retained by the template-based segmentation).  
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Dr Mistry produced NAWM masks by subtracting dilated WML maps from white matter volumes. 
These masks were applied to the MTR volumes (which had been registered to the MPRAGE by Dr 
Mougin), to calculate the average MTR of the NAWM for each subject. If non-dilated WML maps 
had been subtracted, the resulting “NAWM” would be polluted by the inclusion of WML edge-
related signal, giving a false-positive correlation between WML load and NAWM MTR. NAWM 
segmentation is summarised in figure 5.1. 
 
5.2.4 Statistical methods 
 
Dr Tench devised the statistical methodology which was applied by Dr Mistry. Pearson correlation 
coefficients were calculated between mean MTR of the NAWM, cortical lesion counts and 
volumes, WML volumes, and clinical data; and also to assess correlation between MPRAGE and 
MTR cortical lesion counts. Multiple linear regression analysis was used to determine how strongly 
cortical lesion load predicted NAWM MTR, when controlling for potential confounders. The 
dependent variable was NAWM MTR; independent variables were cortical lesion volume, WML 
volume, EDSS, disease duration, and age. 
 
5.3 Results 
5.3.1 Participants 
 
Nineteen people with MS were recruited: 12 were female; 16 relapsing remitting, 2 secondary 
progressive, and 1 primary progressive. Their median EDSS was 3.0 (range: 0-7.5); mean age 48 
years (range: 32-65); and mean disease duration 7 years (range: 2-19). 
 
5.3.2 Test results 
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Cortical lesion volumes and counts on MPRAGE and MTR images correlated significantly with 
NAWM MTR (shown in table 5.1). Scatter plots showing cortical lesion vs. NAWM MTR data are 
shown in figure 5.2. WML volumes did not correlate significantly with NAWM MTR. In our cohort 
none of the clinical data correlated significantly with NAWM MTR. 
 
Cortical lesion counts obtained using the independent contrast mechanisms of MPRAGE and MTR 
correlated significantly with each other (r = 0.842, p = 0.000003; figure 5.3). Examples of cortical 
lesions detected using MPRAGE and MTR cortical ribbons are shown in figure 5.4. 
 
Multiple linear regression analysis showed cortical lesion load was the only variable considered that 
made a significant contribution to the model, with NAWM MTR as the dependent variable, when 
also taking into account age, disease duration, EDSS, and WML volume. Results are summarised in 
table 5.2. ANOVA comparison of models with and without WML volume included as a variable 
(table 5.3) showed no significance (p = 0.786), implying little contribution from WML load. 
 
5.4 Discussion 
 
Our findings are consistent with the hypothesis that cortical lesions cause NAWM axon loss. These 
findings are in keeping with the histopathological precedent that diffuse injury of the NAWM and 
cortical demyelination exist in tandem, and are characteristic hallmarks of primary progressive MS 
(PPMS) and secondary progressive MS (SPMS); furthermore there is a significant correlation 
between the histopathological extent of cortical demyelination and diffuse changes in the NAWM 
(Kutzelnigg et al., 2005). 
 
In our cohort NAWM MTR did not correlate with disability measured using EDSS. This may be 
because our sample size was small and lacked the power to assess correlations beyond our stated 
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objective and because our cohort comprised mostly relapsing remitting MS (RRMS) patients with a 
low EDSS. In a slightly larger study cortical lesion load correlated strongly with physical and 
cognitive disability (Nielsen et al., 2013). The significant correlation we have found between 
cortical lesion load and NAWM MTR does not prove causation, but future larger studies with 
longitudinal follow-up may clarify this. 
 
There is evidence that focal WML load correlates with axon loss specifically within the corpus 
callosum, and that it correlates with grey matter atrophy in the cortex and deep grey matter nuclei 
(Evangelou et al., 2000; Charil et al., 2007; Sepulcre et al., 2009, 2006; Mühlau et al., 2013). 
However, a definite relationship between WML load and whole NAWM or corticospinal tract axon 
loss is evidently absent (Griffin et al., 2002; DeLuca et al., 2006). The presence of microscopic 
inflammation in the NAWM is often used to support the argument that diffuse inflammation causes 
NAWM deterioration. However, neuronal damage caused by other processes, such as Alzheimer’s, 
or even following ischaemic stroke, has been shown to stimulate inflammation (DeGraba, 1998; 
Akiyama et al., 2000). Since inflammation can arise secondarily to neuronal damage, microscopic 
NAWM inflammation does not exclude the possibility that cortical lesions cause NAWM axon loss. 
 
Cortical lesions are less focally destructive than WML (Trapp et al., 1998; Peterson et al., 2001), 
but the remote effects could still be significant. Most central nervous system (CNS) neurons cannot 
divide mitotically and must therefore last a lifetime; this necessitates maintenance and repair. Most 
of the proteins, vesicles, and organelles (including all-important mitochondria) required for axon 
survival are synthesised in the cell body (housing the neuron’s nucleus and ribosomes, figure 5.5), 
and are then transported along the axon as needed (Goldstein and Yang, 2000; Hollenbeck and 
Saxton, 2005). The majority of CNS neurons’ cell bodies reside in the cortex. Even if an 
inflammatory demyelinating cortical lesion only modestly impairs activity within a neuronal cell 
body, this could still lead to the eventual demise of its axon, if the rate of maintenance falls below 
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that required. CNS neurons are among the most metabolically demanding cells in the body. The 
longest axons (e.g. corticospinal tract) maintain cellular processes up to a metre away from their 
cell bodies, and could be the worst affected if their cell bodies are perturbed by cortical lesions.  
 
White matter plaque-centred explanations for the disparity between WML burden and NAWM 
changes remain prevalent. Greater loss of axons inside PPMS WML compared to SPMS WML has 
been interpreted as a cause for greater axon loss in PPMS NAWM despite low WML load 
(Tallantyre, Bø, et al., 2009). However, greater loss of axons inside PPMS WML does not prove 
that inflammatory plaque-formation is more aggressive in PPMS, thereby causing worse NAWM 
pathology. The fact that PPMS WML are smaller on average, and that PPMS WML have a trend 
towards lower inflammatory scores suggest the opposite (Thompson et al., 1990; Tallantyre, Bø, et 
al., 2009). There are two logical possibilities for why intra-lesional axon loss should be worse in 
some cases: either the focal inflammatory insult is more potent, or the substrate (NAWM in this 
context) is frailer at the time of inflammatory injury. When interpreting post mortem “snapshots” it 
is important to remember the context when histopathological features arose. In histopathological 
studies of SPMS WML, most of those lesions exhausted their acute inflammatory phase while the 
subject had RRMS and a less diseased cortex. 
 
A “two-hit” mechanism could better explain axon loss/damage inside WML (figure 5.6). A 
“cortical-hit” comprises cortical MS lesions, causing a “brittle” NAWM, less resilient to subsequent 
inflammation. An “axonal-hit” comprises acute inflammatory WML formation, in the white matter 
tracts functionally connected to the diseased cortex. An axon traversing an acute WML either 
survives and partially recovers, or transects and suffers Wallerian degeneration. The likely outcome 
may depend on whether that neuron had already suffered a cortical-hit. If the two-hit hypothesis is 
correct, newly occurring WML in progressive types of MS would sustain more axon loss than 
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newly occurring WML in RRMS. Longitudinal MTR MRI data from SPMS and RRMS patients 
already supports this (Rocca et al., 1999). 
 
Taken together, cortical lesions’ potential influence on NAWM and a two-hit mechanism could 
explain the relationship between cortical lesions, NAWM, and WML. Overall, these mechanisms 
provide the basis for a corticocentric model of multiple sclerosis pathogenesis. 
 
The present study is limited by the lack of any MRI measure that provides an entirely specific 
appraisal of either axonal density/loss or demyelination within NAWM or focal lesions. Owing to 
this lack of specificity, most MRI techniques can be confounded by intermixed heterogeneous 
pathological processes, including demyelination, axon loss, microglial activation and oedema; this 
is especially true for conventional T2-weighted imaging: an archetype for high sensitivity but low 
specificity. Whilst no existing in vivo technique can duplicate histopathology’s specificity for 
measuring the degree of axonal density, quantitative MRI techniques including MTR go some way 
toward overcoming the limitations of conventional MRI. Furthermore even histopathological 
assessment of axonal density within brain tissue is not without associated difficulties, because 
(compared to study of the spinal cord) the fibre orientation is multidirectional. Post mortem 
historadiological comparisons show that MTR has a strong correlation with the degree of axonal 
loss within focal MS white matter lesions and also NAWM (van Waesberghe et al., 1999). 
Subsequent quantitative histopathological measures of myelin content and axonal density also 
correlate strongly with MTR, whilst the extent of gliosis does not (Schmierer et al., 2004). This is 
corroborated by experimental animal data showing reduction in MTR correlates strongly with 
histopathological findings of demyelination and axon loss within lysolecithin-induced brain plaques 
in primates (Dousset et al., 1995). It is important to note that loss of axons and loss of myelin are 
different processes, between which MTR cannot reliably distinguish; however they are not entirely 
independent processes, indeed quantitative histopathology using post mortem brain slices shows 
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that myelin content and axonal count are strongly associated with each other (Schmierer et al., 
2008). Therefore even though MTR conflates demyelination and axon loss, it may still be of utility 
as an in vivo investigative tool if interpreted sensibly. While post mortem studies indicate that 
demyelination and loss of axons are the main substrates of MTR abnormality in MS, other 
pathological processes described in established MS, such as diffuse astrocytic hyperplasia, patchy 
oedema, and perivascular cellular infiltration are also likely to contribute to the observed reduction 
of MTR values (Rocca et al., 2008). Although acute oedema is undoubtedly a significant 
contributor to the early reduction in MTR of newly-formed or gadolinium-enhancing white matter 
lesions, this potential confounder is less of an issue when considering NAWM, as in this chapter. 
Notwithstanding the complicating effects of axonal integrity, inflammation, changes in water 
content, and axonal neurofilament proteins, the large literature on magnetization transfer imaging 
indicates that MTR is a robust and sensitive measure of tissue damage (Moore and Laule, 2012). 
 
Because of the limitations discussed above, the “two-hit” hypothesis arguably lacks credibility; 
meanwhile post mortem histopathological analysis (despite its specificity) cannot solve that 
conundrum since it has no facility for interval longitudinal assessment. Because the gold-standard 
of whole-brain histopathology is inapplicable to in vivo study, quantitative MRI correlates for 
axonal loss such as MTR at least provide a practicable approach for future longitudinal studies. 
 
In conclusion, cortical lesion load determined using 7T MRI has a significant correlation with 
NAWM MTR. Although it does not prove causation, the correlation implicates cortical lesions in 
the pathogenesis of NAWM axon loss, which underlies progression and disability in MS. A 
corticocentric model for MS pathogenesis invites reconsideration of therapeutic strategies for MS, 
especially if cortical lesions arise by immunopathogenetic mechanisms different to those of WML 
(Choi et al., 2012).  
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Figures and tables 
Figure 5.1 NAWM segmentation 
Top left: 7T MPRAGE MRI; bottom left: 7T MTR image. MPRAGE volumes (a) were 
automatically segmented to produce cortical ribbons (b) and white matter segments (d). Cortical 
ribbons were dilated to produce cortical masks (c), which were subtracted from MPRAGE images 
(a) prior to manual segmentation of WML (e). WML maps were 3D dilated by 5 voxel layers (f), to 
encompass beyond-edge-effects in proximity to lesions. White matter segment masks (d) were 
applied to the MTR volumes (g), which had been co-registered to the MPRAGE. The resultant 
MTR white matter volumes were pruned by subtracting dilated cortical masks (c) and dilated WML 
maps (f), yielding a NAWM MTR volume (h). 
 
MPRAGE = magnetisation prepared rapid acquisition gradient echo; WML = white matter lesion; 
MTR = magnetisation transfer ratio; NAWM = normal appearing white matter 
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Figure 5.2 NAWM MTR vs. cortical lesion load 
Scatter plots showing mean MTR of the NAWM vs. cortical lesion load. Cortical lesion load was 
measured using lesion counts and total cortical lesion volume. This was done using MTR images 
and MPRAGE images. 
 
MTR = magnetisation transfer ratio; NAWM = normal appearing white matter; MPRAGE = 
magnetisation prepared rapid acquisition gradient echo 
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Figure 5.3 MTR cortical lesion counts vs. MPRAGE cortical lesion counts 
Often more cortical lesions were found using MTR than MPRAGE images. Whilst a difference in 
sensitivity is to be expected (since the contrast mechanisms of MTR and MPRAGE are 
independent), a plot of MTR vs. MPRAGE counts appears to intercept the origin. Therefore, though 
the sensitivity of MTR and MPRAGE for cortical lesions differs (and in neither case is likely to be 
100%), they both yielded counts proportional to the true lesion load. 
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Figure 5.4 Examples of cortical lesions 
Left column: 7T MPRAGE MRI; right column 7T MTR images. Two cortical lesions are shown, in 
each case using MPRAGE on the left, and MTR on the right. 
MPRAGE = magnetisation prepared rapid acquisition gradient echo; MTR = magnetisation transfer 
ratio 
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Figure 5.5 Effect of cortical lesion load 
Most of the proteins, vesicles, and organelles (including all-important mitochondria) required for 
axon survival are synthesised in cell bodies (most of which reside in the cortex), and then 
transported along the axon as needed. 
 
 
Image from Wikimedia Commons: the free media repository 
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Figure 5.6 A “two-hit” mechanism might better explain severity of white matter lesion 
axon loss 
 
 
 
 
  
First hit: 
Cortical lesion impairing cellular 
processes and axonal resilience in 
those neurons that survived it. 
Second hit: 
White matter lesion more likely to 
transect those neurons that already 
endured cortical insult. 
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Table 5.1 Pearson correlations of NAWM mean MTR vs. other variables 
 
 
Correlations of variables 
vs. NAWM mean MTR 
MTR cortical lesion 
volume 
MPRAGE cortical 
lesion volume 
MTR cortical lesion 
count 
MPRAGE cortical 
lesion count 
WML volume EDSS Disease duration Age 
Pearson r -0.6874 -0.5706 -0.5572 -0.5385 -0.08706 -0.02662 -0.3205 0.04699 
95% confidence interval -0.8700 to -0.3390 -0.8139 to -0.1570 -0.8072 to -0.1377 -0.7977 to -0.1115 -0.5208 to 0.3824 -0.4752 to 0.4329 -0.6763 to 0.1567 -0.4162 to 0.4908 
p value 0.0006 0.0054 0.0066 0.0087 0.3615 0.4569 0.0905 0.4243 
Significant? (alpha = 0.05) Yes Yes Yes Yes No No No No 
 
 
Correlation with NAWM MTR was significant vs. all measures of cortical lesion load, and was strongest using cortical lesion volumes on MTR 
images. WML volume had no correlation with NAWM MTR. 
 
NAWM = normal appearing white matter; MTR = magnetisation transfer ratio; WML = white matter lesion 
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Table 5.2 Multiple linear regression analysis (including WML volume) 
With WML volume 
included as a variable 
MTR cortical lesion 
volume 
WML volume EDSS Disease duration Age 
t value -3.221 0.277 0.372 -1.213 0.496 
p  value 0.007 0.786 0.716 0.247 0.628 
Significant? (alpha = 0.05) yes no no no no 
 
Multiple linear regression analysis showed cortical lesion load was the only variable considered that made a significant contribution to the model 
(model summary: percentage variance accounted for = 54.8%, p = 0.044).  
MTR = magnetisation transfer ratio; WML = white matter lesion 
 
Table 5.3 Multiple linear regression analysis (excluding WML volume) 
Without WML volume 
included as a variable 
MTR cortical lesion 
volume 
EDSS Disease duration Age 
t value -3.502 0.678 -1.484 0.467 
p  value 0.004 0.509 0.160 0.648 
Significant? (alpha = 0.05) yes no no no 
 
Removing WML volume from the model had little effect on cortical lesion load’s influence on NAWM MTR (model summary: percentage variance 
accounted for = 54.5%, p = 0.019).
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Summary 
 
Owing to a lack of disease-specific tests, diagnosing MS can be protracted and sometimes requires 
multiple, possibly invasive, investigations. In a prospective study, we showed that visualization of 
central veins in brain lesions using 7T T2*-weighted MRI is a sensitive and specific method to 
predict an eventual diagnosis of MS. We studied 29 individuals with suspected MS who had brain 
lesions, and of the 13 individuals who were subsequently diagnosed with MS, all had central veins 
visible in the majority of their brain lesions as detected using 7T MRI. Conversely, the 9 individuals 
in whom a diagnosis of MS was subsequently excluded did not have visible central veins in the 
majority of their brain lesions. 
 
In a cross-sectional study, visualisation of central veins in brain lesions using 3T T2*-weighted 
MRI differentiated 10 individuals with MS from 10 with microangiopathic brain lesions. Based on 
this technique, a “rule of six” was devised that quickly and accurately characterised MS cases in a 
further validation cohort of another 20 individuals with brain lesions (13 of them had MS, the other 
7 were known to have microangiopathic WML related to hypertension associated small-vessel 
ischaemic disease (in 4 cases) or migraine (in 3 cases)). If validated in a large prospective cohort, 
this technique could complement existing diagnostic algorithms by improving the specificity with 
which MRI demonstrates inflammatory demyelinating brain lesions. 
 
Using 7T MRI we found focal MS lesions that would contribute to the abnormalities in NAWM as 
defined using 3T FLAIR MRI. Truer segmentation of NAWM will increase accuracy of analyses 
that include NAWM metrics. 
 
Cortical lesion load correlated with reduction in NAWM MTR in 19 patients with MS. The cortex 
contains so much critical cellular machinery that lesions in the cortex might eventually lead to loss 
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of axons in the white matter, which is the hallmark of progressive MS. Whilst correlation does not 
prove cause, future longitudinal studies may help determine causality.   
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“Holmes gives a demonstration” 
 
 
 
 
 
 
 
 
 
“You will not apply my precept,” he said, shaking his head. “How often have I said to you that 
when you have eliminated the impossible, whatever remains, however improbable, must be the 
truth? We know that he did not come through the door, the window, or the chimney. We also know 
that he could not have been concealed in the room, as there is no concealment possible. Whence, 
then, did he come?” 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
An excerpt from The Sign of Four 
By Sir Arthur Conan Doyle 
 
